

(19)



Europäisches Patentamt  
European Patent Office  
Office européen des brevets

(11) Veröffentlichungsnummer:  
(11) Publication number:  
(11) Numéro de publication:

**0 640 146**

Internationale Anmeldung veröffentlicht durch die  
Weltorganisation für geistiges Eigentum unter der Nummer:

**WO 93/21340** (art.158 des EPf).

International application published by the World  
Intellectual Property Organisation under number:

**WO 93/21340** (art.158 of the EPC).

Demande internationale publiée par l'Organisation  
Mondiale de la Propriété sous le numéro:

**WO 93/21340** (art.158 de la CBE).

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>5</sup> :</b>  C12Q 1/68	<b>A1</b>	<b>(11) International Publication Number:</b> WO 93/21340 <b>(43) International Publication Date:</b> 28 October 1993 (28.10.93)
<b>(21) International Application Number:</b> PCT/GB93/00848 <b>(22) International Filing Date:</b> 22 April 1993 (22.04.93)  <b>(30) Priority data:</b> 9208733.7 22 April 1992 (22.04.92) GB  <b>(71) Applicant (for all designated States except US):</b> MEDICAL RESEARCH COUNCIL [GB/GB]; 20 Park Crescent, London W1N 4AL (GB).  <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only) :</b> ROSENTHAL, André [GB/GB]; 21a Kelvin Close, Cambridge CB1 4DN (GB). BRENNER, Sydney [GB/GB]; 3 Barton Square, Ely, Cambridge CB7 4DF (GB).  <b>(74) Agent:</b> MERCER, Christopher, Paul; Carpmaels & Ransford, 43 Bloomsbury Square, London WC1A 2RA (GB).		<b>(81) Designated States:</b> AT, AU, BB, BG, BR, CA, CH, CZ, DE, DK, ES, FI, GB, HU, JP, KP, KR, KZ, LK, LU, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SK, UA, US, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
<b>(54) Title:</b> DNA SEQUENCING METHOD  <b>(57) Abstract</b>  There is disclosed a method for determining the sequence of a nucleic acid comprising the steps of: a) forming a single-stranded template comprising the nucleic acid to be sequenced; b) hybridising a primer to the template to form a template/primer complex; c) extending the primer by the addition of a single labelled nucleotide; d) determining the type of the labelled nucleotide added onto the primer; e) removing or neutralising the label; and f) repeating steps (c) to (e) sequentially and recording the order of incorporation of labelled nucleotides. There is also disclosed apparatus for carrying out the method.		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	MR	Mauritania
AU	Australia	GA	Gabon	MW	Malawi
BB	Barbados	GB	United Kingdom	NL	Netherlands
BE	Belgium	GN	Guinea	NO	Norway
BF	Burkina Faso	GR	Greece	NZ	New Zealand
BG	Bulgaria	HU	Hungary	PL	Poland
BJ	Benin	IE	Ireland	PT	Portugal
BR	Brazil	IT	Italy	RO	Romania
CA	Canada	JP	Japan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SK	Slovak Republic
CI	Côte d'Ivoire	LI	Liechtenstein	SN	Senegal
CM	Cameroon	LK	Sri Lanka	SU	Soviet Union
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	MC	Monaco	TG	Togo
DE	Germany	MG	Madagascar	UA	Ukraine
DK	Denmark	ML	Mali	US	United States of America
ES	Spain	MN	Mongolia	VN	Viet Nam
FI	Finland				

DNA Sequencing Method

The present invention relates to a method for sequencing DNA. In particular, the present invention concerns a method  
5 for the automated sequencing of large fragments of DNA.

DNA sequence analysis has become one of the most important tools available to the molecular biologist. Current sequencing technology allows sequence data to be obtained  
10 from virtually any DNA fragment. This has allowed not only the sequencing of entire genes and other genomic sequences but also the identification of the sequence of RNA transcripts, by the sequencing of cDNA. Currently, emphasis is being placed on genomic sequencing in order to determine  
15 the DNA sequence of entire genomes. Ultimately, it is hoped that the sequence of the human genome will be deciphered.

Traditional DNA sequencing techniques share three essential steps in their approaches to sequence determination.  
20 Firstly, a multiplicity of DNA fragments are generated from a DNA species which it is intended to sequence. These fragments are incomplete copies of the DNA species to be sequenced. The aim is to produce a ladder of DNA fragments, each a single base longer than the previous one. This can  
25 be achieved by selective chemical degradation of multiple copies of the DNA species to be sequenced, as in the Maxam and Gilbert method (A. Maxam and W. Gilbert, PNAS 74, p.560, 1977). Alternatively, the DNA species can be used as a template for a DNA polymerase to produce a number of  
30 incomplete clones, as in the Sanger method (F. Sanger, S. Nicklen and A. Coulson, PNAS 74, p.5463, 1977). These fragments, which differ in respective length by a single base, are then separated on an apparatus which is capable of resolving single-base differences in size. A thin  
35 polyacrylamide gel is invariably used in this process. The third and final step is the determination of the nature of the base at the end of each fragment. When ordered by the size of the fragments which they terminate, these bases



represent the sequence of the original DNA species.

Determination of the nature of each base is achieved by previously selecting the terminal base of each fragment. In  
5 the Sanger method, for example, dideoxy nucleoside triphosphates (ddNTPs) are used to selectively terminate growing DNA clones at an A, C, G or T residue. This means that four separate reactions need to be performed for each sequencing exercise, each in a separate tube using a  
10 different ddNTP. In one tube, therefore, each labelled fragment will terminate with an A residue, while in the next tube with a C residue, and so on. Separation of each group of fragments side-by-side on a polyacrylamide gel will show the sequence of the template by way of the relative size of  
15 the individual fragments.

In the Maxam and Gilbert method, on the other hand, the selectivity is achieved during the chemical degradation process. Chemicals are used which cleave DNA strands at A  
20 only, C only, G and A or T and C. Use of limiting concentrations of such chemicals allows partial digestion of the DNA species. As in the Sanger method, four separate reactions must be performed and the products separated side-by-side on a polyacrylamide gel.

25

The disadvantages of these prior art methods are numerous. They require a number of complex manipulations to be performed, in at least four tubes. They are susceptible to errors due to the formation of secondary structures in DNA,  
30 or other phenomena that prevent faithful replication of a DNA template in the Sanger method or which cause base-specificity to be lost by the chemical reactants of the Maxam and Gilbert method. The most serious problems, however, are caused by the requirement for the DNA fragments  
35 to be size-separated on a polyacrylamide gel. This process is time-consuming, uses large quantities of expensive chemicals, and severely limits the number of bases which can be sequenced in any single experiment, due to the limited

resolution of the gel. Furthermore, reading the gels in order to extract the data is labour-intensive and slow.

A number of improvements have been effected to these sequencing methods in order to improve the efficiency and speed of DNA sequencing. Some of these improvements have related to the sequencing reaction itself. For example, improved polymerase enzymes have been introduced which lead to greater precision in the Sanger method, such as Sequenase® and Taquenase®. Improved reagents have not, however, significantly affected the speed of sequence data generation or significantly simplified the sequencing process.

In the interest of both speed and simplicity, a number of "Automated Sequencers" have been introduced in recent years (reviewed in T. Hunkapiller, R. Kaiser, B. Koop and L. Hood, Science, 254, p.59, 1991). These machines are not, however, truly automatic sequencers. They are merely automatic gel readers, which require the standard sequencing reactions to be carried out before samples are loaded onto the gel. They do provide a slight increase in speed, however, due to faster reading of the gels and collation of the data generated into computers for subsequent analysis.

Many automated sequencers exploit recent developments which have been made in labelling technology. Traditionally, radioactive labels in the form of  $^{32}\text{P}$  or  $^{35}\text{S}$  have been used to label each DNA fragment. Recently, however, fluorophores have gained acceptance as labels. These dyes, attached either to the sequencing primer or to nucleotides, are excited to a fluorescent state on the polyacrylamide gel by a laser beam. An automated sequencer, therefore, can detect labelled fragments as they pass under a laser in a reading area. Use of dyes which fluoresce at different wavelengths allows individual labelling of A, G, C and T residues, which permits the products of all four sequencing reactions to be run in a single lane of the gel.

Even incorporating such refinements, however, automated sequencers can still produce no more than about 100kb of finished sequence per person per year. At this rate, it  
5 would take one person 73,000 years to sequence the human genome.

Clearly, if the aim of sequencing the human genome is to be achieved, current sequencing technology is entirely  
10 inadequate. In view of this, a few proposals have been made for alternative sequencing strategies which are not merely improvements of the old technology.

One such method, sequencing by hybridisation (SBH), relies  
15 on the mathematical demonstration that the sequence of a relatively short (say, 100kbp) fragment of DNA may be obtained by synthesising all possible N-mer oligonucleotides and determining which oligonucleotides hybridise to the fragment without a single mismatch (R. Drmanac, I. Labat, I.  
20 Bruckner and R. Crkvenjakov, *Genomics*, 4, p.114, 1989; R. Drmanac, Z. Stvanovic, R. Crkvenjakov, *DNA Cell Biology*, 9, p.527, 1990; W. Bains and G. Smith, *J. Theor. Biol.*, 135, pp.303-307, 1988; K.R. Khrapko, et al, *FEBS lett.*, 256, pp.118-122, 1989; P.A. Pevzner, *J. Biomolecular Structure and*  
25 *Dynamics*, 7, pp.63-73, 1989; U. Maskos and E.M. Southern, *Cold Spring Harbour Symposium on Genome Mapping and Sequencing, Abstracts*, p.143, 1991). N can be 8, 9 or 10, such sizes being a compromise between the requirement for reasonable hybridisation parameters and manageable library  
30 sizes.

The technique can be automated by attaching the oligonucleotides in a known pattern on a two-dimensional grid. The fragment to be sequenced is subsequently  
35 hybridised to the oligonucleotides on the grid and the oligonucleotides to which the sequence has been hybridised are detected using a computerised detector. Determination of the sequence of the DNA is then a matter of computation.

However, errors arise from the difficulty in determining the difference between perfect matches and single base-pair mismatches. Repetitive sequences, which occur quite  
5 commonly in the human genome, can also be a problem.

Another proposal involves the fluorescent detection of single molecules (J. Jett et al., J. Biomol. Struct. Dyn., 7, p.301, 1989; D. Nguyen, et al., Anal. Chem., 56, p.348,  
10 1987). In this method, a single, large DNA molecule is suspended in a flow stream using light pressure from a pair of laser beams. Individual bases, each of which is labelled with a distinguishing fluorophore, are then cut from the end of the molecule and carried through a fluorescence detector  
15 by the flow stream.

Potentially, this method could allow the accurate sequencing of a large number of base pairs - several hundred - per second. However, feasibility of this method is not yet  
20 proven.

A third method is sequencing by scanning tunnelling microscopy (STM) (S. Lindsay, et al., Genet. Anal. Tech. Appl., 8, p.8, 1991; D. Allison et al., Scanning Microsc.,  
25 4, p.517, 1990; R. Driscoll et al., Nature, 346, p.294, 1990; M. Salmeron et al., J. Vac. Sci. Technol., 8, p.635, 1990). This technique requires direct three-dimensional imaging of a DNA molecule using STM. Although images of the individual bases can be obtained, interpretation of these  
30 images remains very difficult. The procedure is as yet unreliable and the success rate is low.

A fourth method involves the detection of the pyrophosphate group released as a result of the polymerisation reaction  
35 which occurs when a nucleotide is added to a DNA primer in a primer extension reaction (E.D. Hyman, Anal. Biochem., 174, p. 423, 1988). This method attempts to detect the addition of single nucleotides to a primer using the

luciferase enzyme to produce a signal on the release of pyrophosphate. However, this method suffers a number of drawbacks, not least of which is that dATP is a substrate for luciferase and thus will always give a signal, whether  
5 it is incorporated into the chain or not. The added nucleotides are not labelled and no method is disclosed which will allow the use of labelled nucleotides.

In summary, therefore, each of the new approaches to DNA  
10 sequencing described above, while solving some of the problems associated with traditional methods, introduces several problems of its own. In general, most of these methods are expensive and not currently feasible.

15 There is therefore a need for a sequencing method which allows the rapid, unambiguous sequencing of DNA at low cost. The requirements for such a system are that:

1. it should not be based on gel resolution of  
20 differently-sized oligomers;
2. it should allow more rapid sequencing than present methods;
- 25 3. it should allow several DNA clones to be processed in parallel;
4. the cost of hardware should be reasonable;
- 30 5. it should cost less per base of sequence than current technology; and
6. it should be technically feasible at the present time.

35 The present invention provides such a sequencing system which comprises a method for the sequential addition of nucleotides to a primer on a DNA template.

According to a first aspect of the present invention, there is provided a method for determining the sequence of a nucleic acid comprising the steps of:

- 5 a) forming a single-stranded template comprising the nucleic acid to be sequenced;
- b) hybridising a primer to the template to form a template/primer complex;
- 10 c) extending the primer by the addition of a single labelled nucleotide;
- d) determining the type of the labelled nucleotide added  
15 onto the primer;
- e) removing or neutralising the label; and
- f) repeating steps (c) to (e) sequentially and recording  
20 the order of incorporation of labelled nucleotides.

In the method of the invention, a single-stranded template is generated from a nucleic acid fragment which it is desired to sequence. Preferably, the nucleic acid is DNA.  
25 Part of the sequence of this fragment may be known, so that a specific primer may be constructed and hybridised to the template. Alternatively, a linker may be ligated to a fragment of unknown sequence in order to allow for hybridisation of a primer.

30

The template may be linear or circular. Preferably, the template is bound to a solid-phase support. For example, the template may be bound to a pin, a glass plate or a sequencing chip. The provision of a solid phase template  
35 allows for the quick and efficient addition and removal of reagents, particularly if the process of the invention is automated. Additionally, many samples may be processed in parallel in the same vessel yet kept separate.

Preferably, the template is attached to the solid support by means of a binding linker. For example, one of the commercially available universal primers can be ligated to the 5' end of the template or incorporated easily to one of the ends of the templates by the polymerase chain reaction.

The binding linker may be attached to the solid support by means of a biotin/streptavidin coupling system. For example, the surface of the solid support may be derivatised by applying biotin followed by streptavidin. A biotinylated binding linker is then ligated to the template to bind it to the solid support or the biotinylated template generated by PCR is bound to the solid support.

In an alternative embodiment, an unligated binding linker is bound to the solid support by the biotin/streptavidin system. The template is then hybridised to the binding linker. The binding linker may be a separate binding linker, which is not the sequencing primer. Alternatively, the binding linker may also function as the sequencing primer.

Clearly, it is essential in the latter embodiment that the template should possess a region of complementarity with the binding linker bound to the support. Where the template is ligated to a linker, the complementarity may be provided by that linker. Alternatively, the binding linker may be complementary to a unique sequence within the template itself.

Preferably the solid support is derivatised using a mask so as to allow high resolution packaging of the template(s) on the support. An array of template attachment areas can thereby be produced on a glass plate or sequencing chip, allowing parallel processing of a large number of different templates. Where pins are used as the solid support, a single pin is needed for each template. The single pins may

be grouped into arrays. It is envisaged that an array of 100 x 100 pins or attachment areas can be used, to allow the simultaneous processing of  $10^4$  clones.

- 5 The primer is extended by a DNA polymerase in the presence of a single labelled nucleotide, either A, C, G or T. Suitable DNA polymerases are, for example, Sequenase 2.0®, T4 DNA polymerase or the Klenow fragment of DNA polymerase 1 as well as heat-stable polymerases such as Taq polymerase  
10 (for example Taquenase®) and Vent polymerase.

In a manually operated procedure using a single template, the labelled nucleotides are used singly and sequentially in order to attempt to add that nucleotide to the primer. The  
15 nucleotide will add on to the primer when it is complementary to the next nucleotide in the template. It may take one, two, three or four steps before the appropriate labelled nucleotide is used. However, as soon as it is determined that a labelled nucleotide has been  
20 added onto the primer, step (e) can be performed.

In an automated procedure, especially where a large number of templates are being sequenced simultaneously, in step (c) all four labelled nucleotides are used sequentially and it  
25 is merely noted which of the labelled nucleotides is added, that is it is determined whether it is the first, second, third or fourth labelled nucleotide which is added.

It has been found that nonspecific end-addition and  
30 misincorporation of nucleotides can lead to background problems when the incorporation step has been repeated a number of times. These side reactions are mainly due to the fact that a single nucleotide is present, instead of all four nucleoside triphosphates. In fact, it has been  
35 observed that while it is possible to sequence certain templates by the sequential addition of single nucleotides in the absence of the other three, significant problems have been encountered with other templates, particularly those



templates containing multiple base repeats, due to non-specific incorporation of a nucleotide which is caused by the polymerase effectively jumping over a non-complementary base.

5

In order to ensure high accuracy of operation during the primer extension step, it has been found advantageous to carry out step (c) in the presence of chain elongation inhibitors.

10

Chain elongation inhibitors are nucleotide analogues which either are chain terminators which prevent further addition by the polymerase of nucleotides to the 3' end of the chain by becoming incorporated into the chain themselves, or  
15 compete for incorporation without actually becoming incorporated. Preferably, the chain elongation inhibitors are dideoxy nucleotides. Where the chain elongation inhibitors are incorporated into the growing polynucleotide chain, it is essential that they be removed after  
20 incorporation of the labelled nucleotide has been detected, in order to allow the sequencing reaction to proceed using different labelled nucleotides. It has been found, as described below, that 3' to 5' exonucleases such as, for example, exonuclease III, are able to remove  
25 dideoxynucleotides. This finding allows the use of dideoxynucleotides as chain elongation inhibitors to promote the accuracy of the polymerase in the sequencing method of the invention. Accuracy of the polymerase is essential if  $10^4$  clones are to be processed simultaneously, since it is  
30 high polymerase accuracy which enables the sequencing reaction to be carried out on a single template instead of as four separate reactions.

Alternatively, the chain elongation inhibitors may be  
35 deoxynucleoside 5'-[ $\alpha$ ,  $\beta$ -methylene] triphosphates. These compounds are not incorporated into the chain. Other nucleotide derivatives such as, for example, deoxynucleoside diphosphates or deoxynucleoside monophosphates may be used

which are also not incorporated into the chain.

It is furthermore envisaged that blocking groups on the 3' moiety of the deoxyribose group of the labelled nucleotide  
5 may be used to prevent nonspecific incorporation. Preferably, therefore, the labelled nucleotide is labelled by attachment of a fluorescent dye group to the 3' moiety of the deoxyribose group, and the label is removed by cleaving  
10 the fluorescent dye from the nucleotide to generate a 3' hydroxyl group. The fluorescent dye is preferably linked to the deoxyribose by a linker arm which is easily cleaved by chemical or enzymatic means.

Evidently, when nucleotide analogue chain elongation  
15 inhibitors are used, only the analogues which do not correspond to the labelled nucleotide should be added. Such analogues are referred to herein as heterogenous chain elongation inhibitors.

20 Label is ideally only incorporated into the template/primer complex if the labelled nucleotide added to the reaction is complementary to the nucleotide on the template adjacent the 3' end of the primer. The template is subsequently washed to remove any unincorporated label and the presence  
25 of any incorporated label determined. A radioactive label may be determined by counting or any other method known in the art, while fluorescent labels can be induced to fluoresce, for example by laser excitation.

30 It will be apparent that any label known in the art to be suitable for labelling nucleic acids may be used in the present invention. However, the use of fluorescent labels is currently preferred, due to the sensitivity of detection systems presently available for such labels which do not  
35 involve the use of radioactive substances.

Examples of fluorescently-labelled nucleotides currently available include fluorescein-12-dUTP, fluorescein-15-dCTP,

fluorescein-15-dATP and fluorescein-15-dITP. It has proved very difficult to synthesise a suitable fluorescent guanosine compound, so an inosine compound is used in its place. Should a fluorescent guanosine compound become  
5 available, its use is envisaged in the present invention.

It has been found advantageous to use a mixture of unlabelled and labelled nucleotides in the addition step.

10 When a fluorescent label is used, in order to produce all possible extension products on a template possessing a run of a particular nucleotide, the following ratios were found to be approximately optimal:

15	Fluorescein - 15-dATP/dATP	500:1
	Fluorescein - 15-dITP/dGTP	500:1
	Fluorescein - 12-dUTP/dTTP	15:1
	Fluorescein - 12-dCTP/dCTP	15:1.

20 Preferably, therefore, the above ratios are used in connection with fluorescently - labelled nucleotides.

By repeating the incorporation and label detection steps until incorporation is detected, the nucleotide on the  
25 template adjacent the 3' end of the primer may be identified. Once this has been achieved, the label must be removed before repeating the process to discover the identity of the next nucleotide. Removal of the label may be effected by removal of the labelled nucleotide using a  
30 3'-5' exonuclease and subsequent replacement with an unlabelled nucleotide. Alternatively, the labelling group can be removed from the nucleotide. In a further alternative, where the label is a fluorescent label, it is possible to neutralise the label by bleaching it with laser  
35 radiation.

If chain terminators or 3' blocking groups have been used, these should be removed before the next cycle can take

place. Preferably, chain terminators are removed with a 3'-5' exonuclease. Preferably, exonuclease III is used. 3' blocking groups may be removed by chemical or enzymatic cleavage of the blocking group from the nucleotide.

5

Where exonuclease III is used to remove the chain terminators, it is essential to prevent the exonuclease III from chewing back along the growing chain to remove nucleotides which have already been incorporated, or even  
10 the primer itself. Preferably, therefore, a nucleoside derivative which is resistant to removal by exonucleases is used to replace the labelled nucleotides. Advantageously deoxynucleoside phosphorothioate triphosphates ( $d_sNTPs$ ) are used. Likewise, the primer preferably comprises a  
15 phosphorothioate nucleoside base(s) at its 3' end which are incorporated during primer synthesis or an extra enzymatic capping step.

It is known that deoxynucleoside phosphorothioate  
20 derivatives resist digestion by exonuclease III (S. Labeit et al., DNA, 5, p.173, 1986). This resistance is, however, not complete and conditions should be adjusted to ensure that excess digestion and removal of phosphorothioate bases does not occur.

25

For example, it has been found that the pH of the exoIII buffer used (50mM Tris/HCl, 5mM  $MgCl_2$ ) affects the extent of chewing back which occurs. Experiments carried out at pH 6.0, 7.0, 7.5, 8.0, 8.5, 9.0 and 10.0 (37°C) reveal that pH  
30 10.0 is the optimum with respect to the rate of reaction and specificity of exoIII. At this pH, the reaction was shown to go to completion in less than 1 minute with no detectable chewing back.

35 Once the label and terminators/blocking groups have been removed, the cycle is repeated to discover the identity of the next nucleotide.

In an alternative embodiment of the invention, steps (c) and (d) of the first aspect of the invention are repeated sequentially a plurality of times before removal or neutralisation of the label.

5

The number of times the steps (c) and (d) can be repeated depends on the sensitivity of the apparatus used to detect when a labelled nucleotide has been added onto the primer. For instance, if each nucleotide is labelled with a different fluorescent label, the detection apparatus will need to be able to distinguish between each of the labels and will ideally be able to count the number of each type of fluorescent label. Alternatively, where each nucleotide is radioactively labelled or labelled with the same fluorescent dye, the apparatus will need to be able to count the total number of labels added to the primer.

10  
15

As with the first embodiment of the invention, in a manual procedure using a single template, the labelled nucleotides are used singly and sequentially until a labelled nucleotide is added, whereupon the sequence is repeated. In an automated procedure all four labelled nucleotides are used sequentially and the apparatus is programmed to detect which nucleotides are added in what sequence to the primer.

20  
25

Once the number of labels added has reached the resolving power of the detecting apparatus, removal or neutralisation of the label is carried out in a single step. Thus, the number of label removal steps is significantly reduced.

30

In this alternative embodiment, the steps (c) and (d) of the first aspect of the invention will preferably comprise:

- i) adding a labelled nucleotide together with three heterogenous chain elongation inhibitors which are not incorporated into the chain, such as 5'-[ $\alpha$ ,  $\beta$ -methylene] triphosphates;

35

- ii) removing excess reagents by washing;
- iii) determining whether the label has been incorporated;  
and
- iv) repeating steps (i) to (iii) using a different  
labelled nucleotide, either until a labelled nucleotide has  
been incorporated or until all four labelled nucleotides  
have been used.

10

This technique necessitates the use of a more sophisticated counter or label measuring device. Allowing for runs of repeated nucleotides, the label measuring device should be able to detect the presence of between four and sixteen  
15 labelled nucleotides accurately. For the measurement of long stretches of repeated nucleotides, a device with a greater capacity may be required.

#### Scheme 1

20

According to a preferred aspect of the invention, a DNA fragment is sequenced according to the following scheme:

- 1) a capped primer containing a phosphorothioate  
25 nucleoside derivative is hybridized to a template to form a template/primer complex;
- 2) a labelled deoxynucleoside triphosphate (dNTP)  
together with heterogenous chain terminators and a suitable  
30 polymerase is added to the template/primer complex;
- 3) excess reagents are removed by washing;
- 4) the amount of incorporated label is measured;
- 5) the template/primer complex is treated with an  
35 exonuclease to remove the label and the dideoxynucleotides;

- 6) the exonuclease is removed by washing;
- 7) a phosphorothioate deoxynucleoside triphosphate corresponding to the labelled deoxynucleoside triphosphate added in Step 2 is added together with heterogenous chain terminators;
- 8) excess reagents are removed by washing;
- 9) the template/primer complex is treated with an exonuclease to remove the chain terminators;
- 10) the exonuclease is removed by washing; and
- 11) repeating step 2) to 10) four times, each time with a different labelled nucleotide, together with the appropriate heterogenous chain terminators.

For example, in Step 2 above the labelled nucleotide could be dATP. In this case, the heterogeneous chain terminators could be ddGTP, ddTTP and ddCTP. In step 7 phosphorothioate dATP would be added to replace the labelled dATP removed with the exonuclease in step 6. The cycle can then be repeated with another labelled nucleotide, for example dGTP, together with the heterogeneous dideoxynucleotides ddATP, ddTTP and ddCTP. This will cause label to be incorporated in all the chains propagating with G. This is followed in turn with labelled dTTP and labelled dCTP and continued again with dATP, dGTP, dTTP and dCTP and so on.

#### Scheme 2

According to a second preferred aspect of the invention, a DNA fragment is sequenced according to the following scheme:

- 1) a capped primer containing a phosphorothioate nucleoside derivative is hybridized to a template to form a template/primer complex;

- 2) a labelled deoxynucleotide together with heterogeneous chain terminators and a suitable polymerase is added to the template/primer complex;
- 5 3) excess reagents are removed by washing;
- 4) the amount of incorporated label is measured;
- 10 5) the labelled nucleotide and the chain terminators are removed with an exonuclease;
- 6) the exonuclease is removed by washing;
- 15 7) a phosphorothioate deoxynucleotide together with heterogeneous chain elongation inhibitors not incorporated into the chain is added;
- 8) excess reagents are removed by washing; and
- 20 9) steps 2) to 8) are repeated four times, each time with a different labelled nucleotide.

This scheme is essentially a sub-scheme of scheme 1. The main difference is that during the capping step 7, dideoxynucleotides are replaced by the corresponding 5'-[ $\alpha$ ,  $\beta$ -methylene] triphosphates derivatives. However, other chain elongation inhibitors like deoxynucleoside diphosphate or deoxynucleoside monophosphate derivatives may also be used. Since these derivatives cannot be incorporated into the growing polynucleotide chain there is no need to remove them. Hence, scheme 2 completely lacks the last exonuclease treatment step and the subsequent washing step of scheme 1.

35

Scheme 3

According to a third preferred aspect of the invention, a



DNA fragment is sequenced according to the following scheme:

- 1) a capped primer containing a phosphorothioate deoxynucleotide is hybridised to a template to form a  
5 template/primer complex;
- 2) a labelled nucleotide triphosphate together with heterogeneous chain elongation inhibitors not incorporated into the chain is added;
- 10 3) excess reagents are removed by washing;
- 4) the amount of incorporated label is measured;
- 15 5) steps 2 to 4, adding different labelled nucleotides in the presence of their corresponding heterogeneous chain elongation inhibitors not incorporated into the chain, are repeated until all four labelled nucleotides have been added;
- 20 6) all labelled nucleotides are removed with exonuclease;
- 7) the exonuclease is removed by washing;
- 25 8) the phosphorothioate deoxynucleotide corresponding to the first labelled deoxynucleotide added to the reaction in step 2, is added together with heterogeneous chain elongation inhibitors not incorporated into the chain and a suitable polymerase;
- 30 9) excess reagents are removed by washing; and
- 10) steps 8 and 9 are repeated with the three remaining phosphorothioate deoxynucleoside derivatives.

35

This scheme has the notable advantage of reducing overall number of exonuclease steps. All four labelled nucleotides are sequentially added to the chain and individually

detected before all incorporated nucleotides are removed by a single exonuclease digestion step. The chase reactions are then carried out sequentially with the appropriate phosphorothioate nucleoside derivatives.

5

Scheme 4

In a fourth preferred aspect of the invention, a DNA fragment is sequenced according to the following scheme:

10

- 1) a capped primer is hybridized to a template to form a template/primer complex;
- 2) a fluorescent nucleoside triphosphate, together with  
15 three heterogeneous chain elongation inhibitors not incorporated into the chain and a suitable polymerase, is added;
- 3) excess reagents are removed by washing;
- 20 4) the amount of incorporated label is measured;
- 5) steps 2 to 4 are repeated using all three different nucleoside triphosphates, each with a fluorescent label, in  
25 the presence of the respective heterogeneous chain elongation inhibitors not incorporated into the chain.
- 6) the fluorescent labels are destroyed by bleaching with a laser or by a suitable chemical reaction, or the  
30 fluorescent labels are removed by a chemical cleavage step.

This scheme has the advantage that no enzymatic removal of incorporated label by way of an exonuclease reaction is required, nor is a chasing reaction with a phosphorothioate  
35 nucleotide derivative necessary. Instead, all incorporated fluorophores are chemically destroyed using either laser bleaching technology or suitable chemical reactions to destroy the dye or cleave the dye from the nucleotides.

Preferably, if the detector used permits quantitative measurement of incorporated label, the bleaching or cleaving step need only be carried out from time to time rather than after each successive addition.

5

Scheme 5

According to a fifth preferred aspect of the invention a DNA fragment is sequenced according to the following scheme:

10

- 1) a capped primer is hybridized to a template;
- 2) a nucleoside triphosphate labelled by attachment of a fluorescent dye group via a linker arm to the 3' moiety of  
15 the deoxyribose sugar thereon is added;
- 3) excess reagents are removed by washing;
- 4) the amount of incorporated label is measured;
- 20 5) the fluorescent dye group is removed by enzymatic cleavage; and
- 6) excess reagents are removed by washing.

25

In Scheme 5, the nonspecific addition of labelled nucleotide is prevented by the 3' modification, so that the labelled nucleotide effectively acts as a chain terminator. Removal of the 3' blocking group is then all that is required to  
30 allow chain elongation to continue.

In a further aspect of the invention, there is provided a sequencing kit comprising at least three of the following:

- 35 i) a linker for attaching a DNA template to a solid-phase matrix, the linker comprising a primer having a deoxynucleoside phosphorothioate residue at its 3' end;

- ii) chain elongation inhibitors;
- iii) fluorescently-labelled nucleoside triphosphates;
- 5 iv) deoxynucleoside phosphorothioate triphosphates;
- v) a 5'→3' DNA polymerase;
- vi) a 3'→5' exonuclease.

10

In addition, such a kit may comprise a solid support for carrying out the reaction, as well as biotinylated primers or linkers and biotin/streptavidin reagents for coupling the linker to the solid support. The 3'→5' exonuclease may be  
15 exonuclease III. Furthermore, alternative chain elongation inhibitors, such as 3'-deoxyribose blocked labelled nucleotides, may be included. Preferably, the kit will comprise all of the components i-vi.

- 20 The invention also comprises an automatic sequencing machine capable of sequencing a nucleic acid essentially by executing the steps of a method according to the invention.

The machine is adapted either to move the solid support  
25 carrying the template(s) into and out of all the necessary reagent and washing solutions, or to pump reagents and washing solutions over the solid support sequentially. The pin array type of support is better suited to the first procedure, while glass plates and sequencing chips are more  
30 appropriate to the second.

Several washing steps are included between each reagent addition to minimise the carry-over of reagents.

- 35 The presence of label may be determined, in the case of a chip array, by passing the array over a fixed detector which records the level of label relative to the position of the array over the detector. In the case of a fixed glass plate

or sequencing chip array, a radioactive or fluorescent image may be obtained by a fixed detector positioned above the array. Alternatively, the glass plate or sequencing chip array and/or the detector may be movable. A two-dimensional  
5 image is produced by the detector and analysed by a computer.

Alternatively, optical fibres connected directly to a sequencing chip or to the pins in a pin array may be used to  
10 transmit data to a processor if used together with fluorescent labels.

The invention will now be described, for the purpose of illustration only, with reference to the following figures:

15

Figure 1 is a graph showing the correlation of emitted fluorescence to the number of nucleotides incorporated, using dUTP-12-fluorescein; and

20 Figure 2 is as figure 1 except that dCTP-12-fluorescein is used.

#### EXAMPLES

##### 25 EXAMPLE 1

##### PREPARATION OF THE DNA TEMPLATE/PRIMER COMPLEX 1

##### Generation of template and binding to solid support

In this example an anchored single-stranded PCR product was  
30 used which was generated by known methods (T. Hultman et al., Nucleic Acids Res., 17, (1989), 4937-4946; D.S.C. Jones et al., DNA Sequence, 1 (1991), 279-283). Briefly, the template was generated by the polymerase chain reaction (PCR) using one biotinylated primer and one normal primer  
35 and the product subsequently bound to streptavidin coated magnetic beads. By treating the anchored double-stranded PCR product with alkali the non-anchored template strand is removed. All the steps were carried out as follows:

PCR was performed in 50  $\mu$ l using 0.5 ml test tubes. The following items were added: 30  $\mu$ l water, 5  $\mu$ l of 10 x PCR buffer (Cetus), 5  $\mu$ l of 2.5 mM dNTP's, 2.5  $\mu$ l of 10  $\mu$ M of the 5'-biotinylated universal reverse primer with the sequence: 5' Bio-AACAGCTATGACCATG 3', 2.5  $\mu$ l of 10  $\mu$ M of the (-20) universal forward primer with the sequence: 5' GTAAAACGACGGCCAGT 3', 1  $\mu$ l of the Bluescript KS plasmid DNA at the concentration 1 ng/ $\mu$ l, 0.5  $\mu$ l (2.5 units) of native Taq polymerase (Cetus). After overlaying with light mineral oil the following cycles were performed: 95°C 90s, [95°C 30s, 55°C 60s, 72°C 60s] x 35, 72°C 180s. All cycles were performed using the maximum heating and cooling rates possible with the Techne PHC-1 or PHC-2.

Binding the biotinylated PCR product with a length of approximately 250 bp to the streptavidin-coated magnetic beads (Dynal) is accomplished by incubating 100  $\mu$ l of beads under mineral oil at room temperature for 5 min. The beads are sedimented using a strong magnet and the supernatant including the mineral oil is removed. Further traces of unused nucleotides, primers and buffers are removed by washing the beads with 100  $\mu$ l of water. The nonbiotinylated DNA strand is removed by incubating the beads with 50  $\mu$ l of 0.15 M NaOH for 5 min. at room temperature. The beads are sedimented and the supernatant is removed, followed by a further treatment with 50  $\mu$ l of 0.15M NaOH and three washings with 100  $\mu$ l of water. Finally the beads were resuspended in 10  $\mu$ l of water.

#### Annealing of the sequencing primer to the anchored single-stranded DNA template

To the 10  $\mu$ l resuspended beads with the anchored single-stranded DNA template (approximately 2 pmoles), 4  $\mu$ l of 5 x Sequenase annealing buffer (200 mM Tris/HCl pH 7.5 100 mM MgCl<sub>2</sub>, 250 mM NaCl, USB), and 4  $\mu$ l (4 pmoles) of T7 primer with the sequence: 5' AATACGACTCACTATAG 3' are added. The

### Capping of the primer with thionucleotides

20 Removing the dideoxynucleotide from the capped primer

30 SEQUENCING BY SEQUENTIAL ADDITION OF SINGLE LABELLED  
NUCLEOTIDES: FIRST COMPLETE CYCLE OF 9 STEPS

Steps 2 and 3.

BNSDOCID: &lt;WO 9321340A1.1&gt;

400 Ci/mmmole, 4  $\mu$ M cold dATP, 100  $\mu$ M ddGTP, 100  $\mu$ M ddTTP, 100  $\mu$ M ddCTP, and 4  $\mu$ l of diluted sequenase 2.0. The mixture was incubated for 2 min at 37°C and the reaction stopped by sedimenting the beads with the magnet and removing the supernatant followed by three further washings with 50  $\mu$ l of water. In this step, according to the complementary strand, two A-nucleotides and one dideoxy T-nucleotide were added to the 3'-end of the capped primer.

10 Step 4

The label is counted with a hand counter

Steps 5 and 6

The dideoxynucleotide and the labelled nucleotides were removed by adding 10  $\mu$ l (20 units) of an exonuclease III solution in 50 mM Tris/HCl pH 7.5, 5 mM MgCl<sub>2</sub>, 5 mM DTT and incubating the mixture for 2 min. at 37°C. The reaction was stopped by sedimenting the beads with the magnet and removing the supernatant, followed by three washings with 50  $\mu$ l of water. The removal of the label was checked by measuring the mixture with the hand counter.

Steps 7 and 8

In order to cap the primer, the beads were resuspended in 13  $\mu$ l water. The following items were added: 5  $\mu$ l 5 x sequenase buffer, 10  $\mu$ l of a nucleotide mixture containing 100  $\mu$ M d<sub>s</sub>ATP, 100  $\mu$ M ddGTP, 100  $\mu$ M ddTTP, 100  $\mu$ M ddCTP, and 4  $\mu$ l of diluted sequenase 2.0. The mixture was incubated 2 min. at 37°C and the reaction stopped by sedimenting the beads with the magnet and removing the supernatant followed by three further washings with 50  $\mu$ l of water. In this step, two thiolated A-nucleotides and one dideoxy T-nucleotide were added to the sequencing primer.

35 Steps 9 and 10

The dideoxy nucleotide was removed by adding 10  $\mu$ l (20 units) of the above specified exonuclease III solution and incubating the mixture for 2 min. at 37°C. The reaction was



stopped by sedimenting the beads with the magnet and removing the supernatant, followed by three washings with 50  $\mu$ l of water.

5 SEQUENCING BY SEQUENTIAL ADDITION OF SINGLE NUCLEOTIDES:  
SECOND COMPLETE CYCLE OF 9 STEPS

Scheme 1

Steps 2 and 3

The beads (anchored template/primer complex 1) were  
10 resuspended in 13  $\mu$ l water. The following items were added:  
5  $\mu$ l of 5 x sequenase buffer, 10  $\mu$ l of a nucleotide mixture  
containing 10  $\mu$ Ci of alpha-<sup>32</sup>P dTTP of specific activity of  
400 Ci/mmol, 4  $\mu$ M cold dTTP, 100  $\mu$ M ddGTP, 100  $\mu$ M ddATP, 100  
15  $\mu$ M ddCTP, and 4  $\mu$ l of diluted sequenase 2.0. The mixture  
was incubated 2 min. at 37°C and the reaction stopped by  
sedimenting the beads with the magnet and removing the  
supernatant followed by three further washings with 50  $\mu$ l of  
water. In this step, according to the complementary strand,  
two T-nucleotides and one dideoxy G-nucleotide were added to  
20 the 3'-end of the capped primer.

Step 4

The label is counted with a hand counter.

25 Steps 5 and 6

The dideoxynucleotide and the labelled nucleotides were  
removed by adding 10  $\mu$ l (20 units) of the above specified  
exonuclease III solution and incubating the mixture for 2  
min at 37°C. The reaction was stopped by sedimenting the  
30 beads with the magnet and removing the supernatant, followed  
by three washings with 50  $\mu$ l of water. The removal of the  
label was checked by measuring the mixture with the hand  
counter.

35 Steps 7 and 8

In order to cap the primer, the beads were resuspended in 13  
 $\mu$ l water. The following items were added: 5  $\mu$ l of 5 x  
sequenase buffer, 10  $\mu$ l of a nucleotide mixture containing

100  $\mu$ M d<sub>s</sub>TTP, 100  $\mu$ M ddGTP, 100  $\mu$ M ddATP, 100  $\mu$ M ddCTP, and 4  $\mu$ l of diluted sequenase 2.0. The mixture was incubated 2 min. at 37°C and the reaction stopped by sedimenting the beads with the magnet and removing the supernatant followed  
5 by three further washings with 50  $\mu$ l of water. In this step, two thiolated T-nucleotides and one dideoxy G-nucleotide were added to the sequencing primer.

#### Steps 9 and 10

10 The dideoxy nucleotide was removed by adding 10  $\mu$ l (20 units) of the above specified exonuclease III solution and incubating the mixture for 2 min. at 37°C. The reaction was stopped by sedimenting the beads with the magnet and removing the supernatant, followed by three washings with 50  
15  $\mu$ l of water.

#### **EXAMPLE 2**

This experiment was carried out in order to confirm that all  
20 the reactions described in example 1 yielded the correct elongation as well as degradation products. To prove this, the experiment described in example 1 was repeated using a <sup>32</sup>P-labelled primer in combination with cold nucleotides. The following modifications were made:

25

1. 4 pmoles of a 5'-<sup>32</sup>P-labelled sequencing primer with the sequence 5' AATACGACTCACTATAG 3' was used in the annealing step;
2. In step 2 of the first cycle the labelled compound  
30  $\alpha$ -<sup>32</sup>P-dATP was omitted from the nucleotide mixture and the concentration of the cold dATP was increased to 100  $\mu$ M;
3. In step 2 of the second cycle the labelled compound  $\alpha$ -<sup>32</sup>-dTTP was omitted from the nucleotide mixture and the concentration of the cold dTTP was increased to 100  $\mu$ M;
- 35 4. Step 4 in both cycles was not necessary;
5. After each enzymatic reaction and subsequent washing a 1/100 aliquot of the beads were removed and placed in a separate 0.5 ml test tube.

After performing all steps described in example 1, 5  $\mu$ l of 90% formamide dye mix were added to all the individual bead aliquots, the mixtures heated for 3 min. at 95°C, centrifuged at 13,000g for 5 seconds and cooled on ice. A small aliquot (1  $\mu$ l) of each sample was loaded into a individual well of a 20% polyacrylamide gel containing 7M urea and electrophoresed at 700 Volts for 3 to 4 hours. After electrophoresis the upper glass plate was removed and the exposed to a X-ray film for approximately 2 to 4 hrs. The band pattern obtained was in full agreement with the predicted length of all primer elongation and degradation products.

### 15 EXAMPLE 3

#### PREPARATION OF ANCHORED DNA TEMPLATE/PRIMER COMPLEX 2

##### Annealing and binding of the template/primer complex to solid support

In this example the biotinylated sequencing primer was first annealed to the complementary region of a single-stranded M13 template and the complex subsequently bound via the 5' biotin moiety of the primer to the solid support (streptavidin beads). 2  $\mu$ g (1 pmole) of M13mp18 DNA was combined with 2 pmoles of 5' biotinylated (-20) universal forward primer with the sequence 5' GTAAACGACGGCCAGT 3' in 40 mM Tris/HCl pH 7.5, 20 mM MgCl<sub>2</sub>, 50 mM NaCl in a total of 10  $\mu$ l. The mixture was heated for 3 min. at 65°C and slowly cooled down to room temperature over a period of 10 min. 30  $\mu$ l of streptavidin-coated magnetic beads (Dynal) were added and the mixture incubated for 5 minutes at room temperature. The beads were sedimented, the supernatant removed, and the beads resuspended in 10  $\mu$ l of water.

##### Capping of the primer with thionucleotides

35

To the 18  $\mu$ l annealing mixture add 10  $\mu$ l of 100  $\mu$ M d<sub>s</sub>GTP, ddATP, ddTTP, ddCTP, and 4  $\mu$ l (5 units) of diluted sequenase 2.0 (USB), and incubate the mixture for 2 min. at room

temperature. According to the complementary strand this adds the following two nucleotides sequentially to the primer: d<sub>8</sub>G and ddA. The beads were sedimented using the magnet and the supernatant removed. The beads were then  
5 washed two times with 50  $\mu$ l water.

Removing the dideoxynucleotide from the capped primer

To the bead 10  $\mu$ l (20 units) of an exonuclease solution in 50 mM Tris-HCl pH 7.5, 5 mM MgCl<sub>2</sub>, 5 mM DTT were added and  
10 the mixture incubated 2 min. at 37°C. The reaction was stopped by sedimenting the beads with the magnet and removing the supernatant, followed by three washings with 50  $\mu$ l of water. This step removed the dideoxy A-nucleotide from the 3'-end of the primer.

15

SEQUENCING BY SEQUENTIAL ADDITION OF SINGLE LABELLED NUCLEOTIDES: FIRST COMPLETE CYCLE OF 9 STEPS

Scheme 1

20

Steps 2 and 3.

The beads (anchored template/primer complex 1) were resuspended in 13  $\mu$ l water. The following items were added: 5  $\mu$ l 5 x sequenase buffer, 10  $\mu$ l of a nucleotide mixture  
25 containing 10  $\mu$ Ci of alpha-<sup>32</sup>P dATP of specific activity of 400 Ci-mmol, 4  $\mu$ M cold dATP, 100  $\mu$ M ddGTP, 100  $\mu$ M ddTTP, 100  $\mu$ M ddCTP, and 4  $\mu$ l of diluted sequenase 2.0. The mixture was incubated for 2 min at 37°C and the reaction stopped by sedimenting the beads with the magnet and removing the  
30 supernatant followed by three further washings with 50  $\mu$ l of water. In this step, according to the complementary strand, two A-nucleotides and one dideoxy T-nucleotide were added to the 3' end of the capped primer.

35 Step 4

The label is counted with a hand counter.

Steps 5 and 6

The dideoxynucleotide and the labelled nucleotides were removed by adding 10  $\mu$ l (20 units) of an exonuclease III solution in 50 mM Tris/HCl pH 7.5 mM  $MgCl_2$ , 5 mM DTT and incubating the mixture for 2 min. at 37°C. The reaction was  
5 stopped by sedimenting the beads with the magnet and removing the supernatant, followed by three washings with 50  $\mu$ l of water. The removal of the label was checked by measuring the mixture with the hand counter.

10 Steps 7 and 8

In order to cap the primer, the beads were resuspended in 13  $\mu$ l water. The following items were added: 5  $\mu$ l 5 x sequence buffer, 10  $\mu$ l of a nucleotide mixture containing 100  $\mu$ M  $d_g$ ATP, 100  $\mu$ M ddGTP, 100  $\mu$ M ddTTP, 100  $\mu$ M ddCTP, and 4  $\mu$ l of  
15 diluted sequenase 2.0. The mixture was incubated 2 min. at 37°C and the reaction stopped by sedimenting the beads with the magnet and removing the supernatant followed by three further washings with 50  $\mu$ l of water. In this step, two thiolated A-nucleotides and one dideoxy T-nucleotide were  
20 added to the sequencing primer.

Steps 9 and 10

The dideoxy nucleotide was removed by adding 10  $\mu$ l (20 units) of the above specified exonuclease III solution and  
25 incubating the mixture for 2 min. at 37°C. The reaction was stopped by sedimenting the beads with the magnet and removing the supernatant, followed by three washings with 50  $\mu$ l of water.

30 SEQUENCING BY SEQUENTIAL ADDITION OF SINGLE NUCLEOTIDES:  
SECOND COMPLETE CYCLE OF 9 STEPS

Scheme 1

Steps 2 and 3.

35 The beads (anchored template/primer complex 1) were resuspended in 13  $\mu$ l water. The following items were added: 5  $\mu$ l of 5 x sequenase buffer, 10  $\mu$ l of a nucleotide mixture containing 10  $\mu$ Ci of alpha-<sup>32</sup>-P dTTP of specific activity of

400 Ci/mmol, 4  $\mu$ M cold dTTP, 100  $\mu$ M ddGTP, 100  $\mu$ M ddATP, 100  $\mu$ M ddCTP, and 4  $\mu$ l of diluted sequenase 2.0. The mixture was incubated 2 min. at 37°C and the reaction stopped by sedimenting the beads with the magnet and removing the supernatant followed by three further washings with 50  $\mu$ l of water. In this step, according to the complementary strand, two T-nucleotides and one dideoxy C-nucleotide were added to the 3-end of the capped primer.

10 Step 4

The label is counted with a hand counter.

Steps 5 and 6

15

The dideoxynucleotide and the labelled nucleotides were removed by adding 10  $\mu$ l (20 units) of the above specified exonuclease III solution and incubating the mixture for 2 min. at 37°C. The reaction was stopped by sedimenting the beads with the magnet and removing the supernatant, followed by three washings with 50  $\mu$ l of water. The removal of the label was checked by measuring the mixture with the hand counter.

25 Steps 7 and 8

In order to cap the primer, the beads were resuspended in 13  $\mu$ l water. The following items were added: 5  $\mu$ l of 5 x sequenase buffer, 10  $\mu$ l of a nucleotide mixture containing 100  $\mu$ M d<sub>s</sub>TTP, 100  $\mu$ M ddGTP, 100  $\mu$ M ddATP, 100  $\mu$ M ddCTP, and 4  $\mu$ l of diluted sequenase 2.0. The mixture was incubated 2 min. at 37°C and the reaction stopped by sedimenting the beads with the magnet and removing the supernatant followed by three further washings with 50  $\mu$ l of water. In this step, two thiolated T-nucleotides and one dideoxy C-nucleotide were added to the sequencing primer.

Steps 9 and 10

The dideoxy nucleotide was removed by adding 10  $\mu$ l (20

units) of the above specified exonuclease III solution and incubating the mixture for 2 min. at 37°C. The reaction was stopped by sedimenting the beads with the magnet and removing the supernatant, followed by three washings with 50  
5  $\mu$ l of water.

#### EXAMPLE 4

##### PREPARATION OF THE DNA TEMPLATE/PRIMER COMPLEX 2

10

Template preparation, binding of the template to solid support, and annealing of the sequencing primer was performed as described in example 1, except that in the annealing step 4  $\mu$ l (4 pmoles) of radio-labelled T7 primer  
15 with the sequence:  $^{32}$ P-5'AATACGACTCACTATAG 3' are used.

##### Template/primer complex 2:

Polymer-streptavidin-biotin-

5'-C-C-A-A-T-T-C-G-C-C-C-T-A-T-A-G-T-G-A-G-T-C-G-T-A-T-T----3'

20

3'-G-A-T-A-T-C-A-C-T-C-A-G-C-A-T-A-A- $^{32}$ P-5'

##### Capping of the primer with thionucleotides

To the 18  $\mu$ l annealing mixture add 10  $\mu$ l of 100  $\mu$ M d<sub>s</sub>GTP,  
25 ddATP, ddTTP, and ddCTP and 4  $\mu$ l (5 units) of diluted sequenase 2.0 (USB), and incubate the mixture for 2 min. at room temperature. According to the complementary strand this adds the following three nucleotides sequentially to the primer: d<sub>s</sub>G, d<sub>s</sub>G, ddC. The beads were sedimented using  
30 the magnet and the supernatant removed. The beads were then washed two times with 50  $\mu$ l water.

##### Removing the dideoxynucleotide from the capped primer

35 To the bead 10  $\mu$ l (20 units) of an exonuclease solution in 50 mM Tris/HCl pH 7.5, 5 mM MgCl<sub>2</sub>, 5 mM DTT were added and the mixture incubated 2 min. at 37°C. The reaction was stopped by sedimenting the beads with the magnet and

removing the supernatant, followed by three washings with 50  $\mu$ l of water. This step removed the dideoxy C-nucleotide from the 3'-end of the primer.

#### 5 FIRST SEQUENCING CYCLE (9 STEPS)

##### Scheme 1

##### Steps 2 and 3

10

The beads (anchored template/primer complex 2) were resuspended in 13  $\mu$ l water. The following items were added: 5  $\mu$ l 5 x sequenase buffer, 10  $\mu$ l of a nucleotide mixture containing 100  $\mu$ M dCTP, 100  $\mu$ M ddGTP, 100  $\mu$ M ddATP, 100  $\mu$ M ddTTP, and 4  $\mu$ l of diluted sequenase 2.0. The mixture was incubated for 2 min. at 37°C and the reaction stopped by sedimenting the beads with the magnet and removing the supernatant followed by three further washings with 50  $\mu$ l of water. In this step, according to the complementary strand, 20 one C-nucleotide and one dideoxy G-nucleotide were added to the 3-end of the capped primer.

##### Step 4

This step is omitted because the label is located on the 25 primer.

##### Steps 5 and 6

The dideoxynucleotide and the labelled nucleotides were removed by adding 10  $\mu$ l (20 units) of an exonuclease III 30 solution 50 mM Tris/HCl pH 7.5 mM MgCl<sub>2</sub>, 5 mM DTT and incubating the mixture for 2 min. at 37°C. The reaction was stopped by sedimenting the beads with the magnet and removing the supernatant, followed by three washings with 50  $\mu$ l of water. The removal of the label was checked by 35 measuring the mixture with the hand counter.

##### Steps 7 and 8

In order to cap the primer, the beads were resuspended in 13



5  $\mu$ l water. The following items were added: 5  $\mu$ l 5 x sequenase buffer, 10  $\mu$ l of a nucleotide mixture containing 10  $\mu$ M d<sub>s</sub>CTP, 100  $\mu$ M ddGTP, 100  $\mu$ M ddATP  $\mu$ M ddTTP, and 4  $\mu$ l of diluted sequenase 2.0. The mixture was incubated 2 min. at 37°C and the reaction stopped by sedimenting the beads with the magnet and removing the supernatant followed by three further washings with 50  $\mu$ l of water. In this step, one thiolated C-nucleotide and one dideoxy G-nucleotide were added to the sequencing primer.

10

Steps 9 AND 10

The dideoxy nucleotide was removed by adding 10  $\mu$ l (20 units) of the above specified exonuclease III solution and incubating the mixture for 2 min. at 37°C. The reaction was stopped by sedimenting the beads with the magnet and removing the supernatant, followed by three washings with 50  $\mu$ l of water.

15

## SECOND SEQUENCING CYCLE (9 STEPS)

20

## Scheme 1

Steps 2 and 3

25 The beads (anchored template/primer complex 2) were resuspended in 13  $\mu$ l water. The following items were added: 5  $\mu$ l 5 x sequenase buffer, 10  $\mu$ l of a nucleotide mixture containing 100  $\mu$ M dGTP, 100  $\mu$ M ddATP, 100  $\mu$ M ddTTP, 100  $\mu$ M ddCTP, and 4  $\mu$ l of diluted sequenase 2.0. The mixture was incubated for 2 min. at 37°C and the reaction stopped by sedimenting the beads with the magnet and removing the supernatant followed by three further washings with 50  $\mu$ l of water. In this step, according to the complementary strand, one G-nucleotide and one dideoxy A-nucleotide were added to the 3'-end of the capped primer.

30

35

Step 4

This step is omitted because the label is located on the

primer.

Steps 5 and 6

The dideoxynucleotide and the labelled nucleotides were  
5 removed by adding 10  $\mu$ l (20 units) of an exonuclease III  
solution in 50 mM Tris/HCl pH 7.5, 5 mM  $MgCl_2$ , 5 mM DTT and  
incubating the mixture for 2 min. at 37°C. The reaction was  
stopped by sedimenting the beads with the magnet and  
removing the supernatant, followed by three washings with 50  
10  $\mu$ l of water. The removal of the label was checked by  
measuring the mixture with the hand counter.

Steps 7 and 8

In order to cap the primer, the beads were resuspended in 13  
15  $\mu$ l water. The following items were added: 5  $\mu$ l x sequenase  
buffer, 10  $\mu$ l of a nucleotide mixture containing 100  $\mu$ M  
 $d_s$ GTP, 100  $\mu$ M ddATP, 100  $\mu$ M ddTTP, 100  $\mu$ M ddCTP, and 4  $\mu$ l of  
diluted sequenase 2.0. The mixture was incubated 2 min. at  
37°C and the reaction stopped by sedimenting the beads with  
20 the magnet and removing the supernatant followed by three  
further washings with 50  $\mu$ l of water. In this step, one  
thiolated G-nucleotide and one dideoxy A-nucleotide were  
added to the sequencing primer.

25 Steps 9 and 10

The dideoxy nucleotide was removed by adding 10  $\mu$ l (20  
units) of the above specified exonuclease III solution and  
incubating the mixture for 2 min at 37°C. The reaction was  
stopped by sedimenting the beads with the magnet and  
30 removing the supernatant, followed by three washings with 50  
 $\mu$ l of water.

THIRD SEQUENCING CYCLE (9 STEPS)

35 Scheme 1

Steps 2 and 3

The beads (anchored template/primer complex 2) were

resuspended in 13  $\mu$ l water. The following items were added:  
5  $\mu$ l 5 x sequenase buffer, 10  $\mu$ l of a nucleotide mixture  
containing 100  $\mu$ M dATP, 100  $\mu$ M ddGTP, 100  $\mu$ M ddTTP, 100  $\mu$ M  
ddCTP, and 4  $\mu$ l of diluted sequenase 2.0. The mixture was  
5 incubated for 2 min at 37°C and the reaction stopped by  
sedimenting the beads with the magnet and removing the  
supernatant followed by three further washings with 50  $\mu$ l of  
water. In this step, according to the complementary strand,  
two A-nucleotides and one dideoxy T-nucleotide were added at  
10 the 3'-end of the capped primer.

#### Step 4

This step is omitted because the label is located on the  
primer.

15

#### Steps 5 and 6

The dideoxynucleotide and the labelled nucleotides were  
removed by adding 10  $\mu$ l (20 units) of an exonuclease III  
solution in 50 mM Tris/HCl pH 7.5, 5 mM MgCl<sub>2</sub>, 5 mM DTT and  
20 incubating the mixture for 2 min at 37°C. The reaction was  
stopped by sedimenting the beads with the magnet and  
removing the supernatant, followed by three washings with 50  
 $\mu$ l of water. The removal of the label was checked by  
measuring the mixture with the hand counter.

25

#### Steps 5 and 6

In order to cap the primer, the beads were resuspended in 13  
 $\mu$ l water. The following items were added: 5  $\mu$ l 5 x  
sequenase buffer, 10  $\mu$ l of nucleotide mixture containing 100  
30  $\mu$ M d<sub>s</sub>ATP, 100  $\mu$ M ddGTP, 100  $\mu$ M ddTTP, 100  $\mu$ M ddCTP, and 4  $\mu$ l  
of diluted sequenase 2.0. The mixture was incubated 2 min.  
at 37°C and the reaction stopped by sedimenting the beads  
with the magnet and removing the supernatant followed by  
three further washings with 50  $\mu$ l of water. In this step,  
35 one thiolated A-nucleotide and one dideoxy T-nucleotide were  
added to the sequencing primer.

#### Steps 9 and 10

The dideoxy nucleotide was removed by adding 10  $\mu$ l (20 units) of the above specified exonuclease III solution and incubating the mixture for 2 min at 37°C. The reaction was stopped by sedimenting the beads with the magnet and removing the supernatant, followed by three washings with 50  $\mu$ l of water.

#### FOURTH SEQUENCING CYCLE (9 STEPS)

##### 10 Scheme 1

##### Steps 2 and 3

The beads (anchored template/primer complex 2) were resuspended in 13  $\mu$ l water. The following items were added: 5  $\mu$ l 5 x sequenase buffer, 10  $\mu$ l of a nucleotide mixture containing 10  $\mu$ M dTTP, 100  $\mu$ M ddGTP, 100  $\mu$ M ddATP, 100  $\mu$ M ddCTP, and 4  $\mu$ l of diluted sequenase 2.0. The mixture was incubated for 2 min. at 37°C and the reaction stopped by sedimenting the beads with the magnet and removing the supernatant followed by three further washings with 50  $\mu$ l of water. In this step, according to the complementary strand, two T-nucleotides and one dideoxy G-nucleotide were added to the 3'-end of the capper primer.

25

##### Step 4

This step is omitted because the label located on the primer.

##### 30 Steps 5 and 6

The dideoxynucleotide and the labelled nucleotides were removed by adding 10  $\mu$ l (20 units) of an exonuclease III solution in 50 mM Tris/HCl pH 7.5, 5 mM MgCl<sub>2</sub>, 5 mM DTT and incubating the mixture for 2 min. at 37°C. The reaction was stopped by sedimenting the beads with the magnet and removing the supernatant, followed by three washings with 50  $\mu$ l of water. The removal of the label was checked by measuring the mixture with the hand counter.

Steps 7 and 8

In order to cap the primer, the beads were resuspended in 13  $\mu$ l water. The following items were added: 5  $\mu$ l 5 x sequenase buffer, 10  $\mu$ l of a nucleotide mixture containing 100  $\mu$ M d<sub>5</sub>TTP, 100  $\mu$ M ddGTP, 100  $\mu$ M ddATP, 100  $\mu$ M ddCTP, and 4  $\mu$ l of diluted sequenase 2.0. The mixture was incubated 2 min. at 37°C and the reaction stopped by sedimenting the beads with the magnet and removing the supernatant followed by three further washings with 50  $\mu$ l of water. In this step, one thiolated T-nucleotides and one dideoxy G-nucleotide were added to the sequencing primer.

Steps 9 and 10

The dideoxy nucleotide was removed by adding 10  $\mu$ l (20 units) of the above specified exonuclease III solution and incubating the mixture for 2 min. at 37°C. The reaction was stopped by sedimenting the beads with the magnet and removing the supernatant, followed by three washings with 50  $\mu$ l of water.

## EXAMPLE 5

Fluorescein was used as a single tag attached to all four deoxynucleotides. In particular we used the following fluorescein-labelled deoxynucleoside triphosphates: fluorescein-12-dUTP, fluorescein-15-dATP, fluorescein-15-dCTP, fluorescein-15-dITP.

## 30 GENERATION OF TEMPLATES

As a model template we used two single-stranded PCR products which were derived from the multicloning site of Bluescript II KS. Amplification of the Bluescript II KS vector DNA using the biotinylated M13 (-21) forward primer and the nonbiotinylated M13 reverse primer yielded a PCR product which was anchored via the biotin moiety to streptavidin-coated beads as described in example 1. The nonbiotinylated

(+) strand was removed by incubating the beads with 0.15 M NaOH for 5 minutes followed by a wash with 0.15 M NaOH and three washes with water. The template, comprising the (-) strand of the multicloning site of the Bluescript II KS vector, was named PCR template 1. Amplification of the Bluescript II KS vector using the biotinylated M13 reverse primer and the nonbiotinylated M13 (-21) forward primer yielded a PCR product which was anchored via the biotin moiety to streptavidin-coated beads as described in example 1. The nonbiotinylated (-) strand was removed by incubating the beads with 0.15 M NaOH for 5 minutes followed by a wash with 0.15 M NaOH and three washes with water. This template comprising the (+) strand of the multicloning site of the Bluescript II KS vector was named PCR template 2.

15

#### SYNTHESIS OF 5'-TAMRA LABELLED SPECIFIC OLIGONUCLEOTIDE PRIMERS

For each fluorescently-labelled nucleotide four different primers were designed using the Bluescript sequence of the PCR template 1 and 2. The primers were located in front of runs of a single nucleotide allowing incorporation of one, two, three, four, or five nucleotides of the same kind.

For incorporation of fluorescein-12-dUTP the following primers were synthesized:

Name	Sequence	No. of incorporated fluorescent nucleotides	Nucleotide mix	template
5				
A	5'-TAMRA-ACTATAGGGCGAATTGGAGC	1	dUTP-F, ddCTP	1
K	5'-TAMRA-CGACTCACTATAGGGCGA	2	dATP, dUTP-F, ddGTP	1
G	5'-TAMRA-GGTACCCAGCTTTTGTTC	3	dCTP, dUTP-F, ddATP	1
L	5'-TAMRA-GGGGGCCCGGTACCCAG	4	dCTP, dUTP-F, ddGTP	1
10				

40

For incorporation of fluorescein-15-dCTP the following primers were synthesized:

Name	Sequence	No. of incorporated fluorescent nucleotides	Nucleotide mix	template
15				
G	5'TAMRA-GGTACCCAGCTTTTGTTC	1	dTTP, dCTP, F, ddATP,	1
A	5'TAMRA-ACTATAGGGCGAATTGGAGC	2	dTTP, dCTP-F, ddATP	1
C	5'TAMRA-TACGCCAAGCGCGCAATT	3	dATP, dCTP-F, ddTTP	2
20	D 5'TAMRA-CGCTCTAGAACTAGTGGA	5	dTTP, dCTP, ddGTP	1
25				

41

For incorporation of fluorescein-15-dATP the following primers were synthesized:

Name	Sequence	No. of incorporated fluorescent nucleotides	Nucleotide mix	template
G	5'-TAMRA-GGTACCCAGCTTTTGTTC	1	dCTP, dTTP, dATP-F, ddGTP	1
T3	5'-TAMRA-ATTAACCCCTCACTAAAG	2	dGTP, dATP-F, ddCTP	2
10 E	5'-TAMRA-GCGCAATTAAACCTCACT	3	dATP-F, ddGTP	2
F	5'-TAMRA-AACCCCTCACTAAAGGGA	4	dCTP, dATP-F, ddGTP	1

For incorporation of fluorescein-15-dTTP the following primers were synthesized:

15 Name	Sequence	No. of incorporated fluorescent nucleotides	Nucleotide mix	template
B	5'-TAMRA-GCTATGACCATGATTAC	1	dITP-F, ddCTP	2
T3	5'-TAMRA-ATTAACCCCTCACTAAAG	2	dITP-F, ddATP	2
20 M	5'-TAMRA-CGCGTAATACGACTCACTAT	3	dATP, dITP-F, ddCTP	1
N	5'-TAMRA-GATATCGAATTCCTGCAGCC	4	dCTP-dITP-F, ddATP	1



## ANNEALING

In sixteen different annealing reactions, 2  $\mu$ l of water, 5  $\mu$ l of the appropriate single-stranded PCR template 1 or 2 (see tables), 2  $\mu$ l of 5 x sequenase buffer and 1  $\mu$ l (0.5 pmol) of the appropriate TAMRA-labelled primer (see tables) were combined, heated at 65°C for 3 minutes and then incubated on ice.

## EXTENSION REACTIONS

10

In sixteen different extension reactions, to 6  $\mu$ l of each annealing mix, 2  $\mu$ l of a nucleotide mixture (see tables) containing the appropriate unlabelled dNTPs (at 10  $\mu$ M), the appropriate fluorescently-labelled dNTP (at 10  $\mu$ M), and the appropriate ddNTP (at 10  $\mu$ M), and 2  $\mu$ l of diluted sequenase 2.0 were added and the mixture incubated at 37°C for 3 minutes. The reactions were stopped by adding 5  $\mu$ l of 80% formamide and heated for 3 min at 80°C followed by sedimenting the beads with a magnet and removing the supernatant.

## DETECTION/IMAGING STEP (QUANTITATION)

One  $\mu$ l of each supernatant was measured using a SIT camera (model C2 400-08, Hamamatsu Photonics SA) mounted on a fluorescence microscope. The emitted fluorescence of the rhodamine dye TAMRA located at the 5'-end of the primer and the fluorescein dye introduced by nucleotide incorporation at the 3'-end of the primer was determined for each sample using appropriate filter systems. A control sample of 80% formamide was also measured. The emitted fluorescence  $\Delta I$  fluorescein and  $\Delta I$  rhodamine was recorded. The ratio of  $\Delta I$  fluorescein to  $\Delta I$  rhodamine was used to normalise the data.

35 The results may be summarised as follows:

- Incorporation of up to five fluorescein-labelled pyrimidine nucleotides (fluorescein-12-U, fluorescein-15-C):

-Quantitative measurements show a linear correlation between emitted fluorescence and the number of incorporated fluorescein-labelled pyrimidine nucleotides. No quenching of fluorescence has been observed (see figures 1 and 2).

-Using the above mentioned detection/imaging system from Hamamatsu Photonics we were able to detect as little as  $10^8$  molecules in a volume of approx. 1 nl (concentration: 150 nM), allowing, in principle, the use of up to  $10^4$  different templates on an array of 8 cm x 8 cm.

- Incorporation of up to two fluorescein-labelled purine nucleotides (fluorescein-15-A, fluorescein-15-I). Using the above detector system we were able to measure the difference between one and two fluorescein-labelled purine nucleotides.

#### EXAMPLE 6

##### PREPARATION OF THE DNA TEMPLATE/PRIMER COMPLEX 1

Generation of template and binding to solid support, annealing of the sequencing primer to the anchored single-stranded DNA template, capping of the primer with thionucleotides, and removing of the dideoxynucleotide from the capped primer were carried out as in example 1.

##### SEQUENCING BY SEQUENTIAL ADDITION OF SINGLE FLUORESCENTLY-LABELLED NUCLEOTIDES: FIRST COMPLETE CYCLE OF 9 STEPS.

#### 30 Scheme 1

##### steps 2 and 3

The beads (anchored template/primer complex 1) were resuspended in 4  $\mu$ l water. The following items were added: 2  $\mu$ l 5 x sequenase buffer, 2  $\mu$ l of a nucleotide mix containing 10  $\mu$ M fluorescein-15-dATP (Boehringer Mannheim), 10  $\mu$ M ddGTP, 10  $\mu$ M ddTTP, 10  $\mu$ M ddCTP, and 2  $\mu$ l of diluted sequenase 2.0. The mixture was incubated for 2 min at 37°C and the reaction stopped by sedimenting the beads with the

magnet and removing the supernatant followed by three further washings with 50  $\mu$ l of water. In this step, according to the complementary strand, two fluorescein-15-A-nucleotides and one dideoxy T-nucleotide were added to the 3'- end of the capped primer.

step 4

The fluorescence was measured using a SIT camera (model C2 400-08, Hamamatsu Photonics SA) mounted on a fluorescence microscope.

steps 5 and 6

The dideoxynucleotide and the fluorescently-labelled nucleotides were removed by adding 10  $\mu$ l (20 units) of an exonuclease-III solution in 50 mM Tris/HCl Ph 7.5, 5 mM  $MgCl_2$ , 5 mM DTT and incubating the mixture for 2 min at 37°C. The reaction was stopped by sedimenting the beads with the magnet and removing the supernatant, followed by three washings with 50  $\mu$ l of water.

steps 7 and 8

In order to cap the primer, the beads were resuspended in 4  $\mu$ l water. The following items were added: 2  $\mu$ l 5 x sequenase buffer, 2  $\mu$ l of a nucleotide mixture containing 10  $\mu$ M  $d_5$ ATP, 10  $\mu$ M ddGTP, 10  $\mu$ M ddTTP, 10  $\mu$ M ddCTP, and 2  $\mu$ l of diluted sequenase 2.0. The mixture was incubated for 2 min at 37°C and the reaction stopped by sedimenting the beads with the magnet and removing the supernatant followed by three further washings with 50  $\mu$ l of water. In this step, two thiolated A-nucleotides and one dideoxy T-nucleotide were added to the sequencing primer.

steps 9 and 10

The dideoxy nucleotide was removed by adding 10  $\mu$ l (20 units) of the above specified exonuclease-III solution and incubating the mixture for 2 min at 37°C. The reaction was stopped by sedimenting the beads with the magnet and removing the supernatant, followed by three washing with 50  $\mu$ l of water.

SEQUENCING BY SEQUENTIAL ADDITION OF SINGLE NUCLEOTIDES:  
SECOND COMPLETE CYCLE OF 9 STEPS

5 scheme 1

steps 2 and 3

The beads (anchored template/primer complex 1) were resuspended in 4  $\mu$ l water. The following items were added: 2  $\mu$ l of 5 x sequenase buffer, 2  $\mu$ l of a nucleotide mixture  
10 containing 10  $\mu$ M fluorescein-12-dUTP (Boehringer Mannheim), 10  $\mu$ M ddGTP, 10  $\mu$ M ddATP, 10  $\mu$ M ddCTP, and 2  $\mu$ l of diluted sequenase 2.0. The mixture was incubated 2 min at 37°C and the reaction stopped by sedimenting the beads with the magnet and removing the supernatant followed by three  
15 further washings with 50  $\mu$ l of water. In this step, according to the complementary strand, two fluorescein-labelled U-nucleotides and one dideoxy G-nucleotide were added to the 3'-end of the capped primer.

20 step 4

The fluorescence was measured using a SIT camera (model 400-08, Hamamatsu Photonics SA) mounted on a fluorescence microscope.

25 steps 5 and 6

The dideoxynucleotide and the labelled nucleotides were removed by adding 10  $\mu$ l (20 units) of the above specified exonuclease-III solution and incubating the mixture for 2 min at 37°C. The reaction was stopped by sedimenting the  
30 beads with the magnet and removing the supernatant, followed by three washings with 50  $\mu$ l of water.

steps 7 and 8

In order to cap the primer, the beads were resuspended in 4  
35  $\mu$ l water. The following items were added: 2  $\mu$ l of 5 x sequenase buffer, 2  $\mu$ l of a nucleotide mixture containing 10  $\mu$ M d<sub>s</sub>TTP, 10  $\mu$ M ddGTP, 10  $\mu$ M ddATP, 10  $\mu$ M ddCTP, and 2  $\mu$ l of diluted sequenase 2.0. The mixture was incubated for 2 min

at 37°C and the reaction stopped by sedimenting the beads with the magnet and removing the supernatant followed by three further washings with 50 µl of water. In this step, two thiolated T-nucleotides and one dideoxy G-nucleotide were added to the sequencing primer.

steps 9 and 10

the dideoxy nucleotide was removed by adding 10 µl (20 units) of the above specified exonuclease-III solution and incubating the mixture for 2 min at 37°C. The reaction was stopped by sedimenting the beads with the magnet and removing the supernatant, followed by three washings with 50 µl of water.

15 EXAMPLE 7

PREPARATION OF THE DNA TEMPLATE/PRIMER COMPLEX 1

Generation of template and binding to solid support, annealing of the sequencing primer to the anchored single-stranded DNA template, capping of the primer with thionucleotides, and removing of the dideoxynucleotide from the capped primer were carried out as in example 1.

25 SEQUENCING BY SEQUENTIAL ADDITION OF SINGLE FLUORESCENTLY-LABELLED NUCLEOTIDES: FIRST COMPLETE CYCLE OF 9 STEPS

scheme 1

steps 2 and 3

The beads (anchored template/primer complex 1) were resuspended in 4 µl water. The following items were added: 2 µl 5 x sequenase buffer, 2 µl of a nucleotide mix containing 500 µM fluorescein-15-dATP, 1.0 µM dATP, 10 µM ddGTP, 10 µM ddTTP, 10 µM ddCTP, and 2 µl of diluted sequenase 2.0. The mixture was incubated for 2 min at 37°C and the reaction stopped by sedimenting the beads with the magnet and removing the supernatant followed by three further washings with 50 µl of water. In this step, as directed by the complementary strand, fluorescein-15-A-

nucleotides, A-nucleotides, and one dideoxy T-nucleotide were added to the 3'-end of the capped primer.

step 4

- 5 The fluorescence was measured using a SIT camera (model C2 400-08, Hamamatsu Photonics SA) mounted on a fluorescence microscope.

steps 5 and 6

- 10 The dideoxynucleotide, the deoxynucleotides and the fluorescently-labelled nucleotides were removed by adding 20  $\mu$ l (20 units) of an exonuclease-III solution in 50 mM Tris/HCl pH 7.5, 5 mM  $MgCl_2$ , 5 mM DTT and incubating the mixture for 2 min at 37°C. The reaction was stopped by  
15 sedimenting the beads with the magnet and removing the supernatant, followed by three washings with 50  $\mu$ l of water.

steps 7 and 8

- In order to cap the primer, the beads were resuspended in 4  
20  $\mu$ l water. The following items were added: 2  $\mu$ l 5 x sequenase buffer, 2  $\mu$ l of a nucleotide mixture containing 10  $\mu$ M  $d_s$ ATP, 10  $\mu$ M ddGTP, 10  $\mu$ M ddTTP, 10  $\mu$ M ddCTP, and 2  $\mu$ l of diluted sequenase 2.0. The mixture was incubated for 2 min at 37°C and the reaction stopped by sedimenting the beads  
25 with the magnet and removing the supernatant followed by the three further washings with 50  $\mu$ l of water. In this step, two thiolated A-nucleotides and one dideoxy T-nucleotide were added to the sequencing primer.

30 steps 9 and 10

- The dideoxy nucleotide was removed by adding 10  $\mu$ l (20 units) of the above specified exonuclease-III solution and incubating the mixture for 2 min at 37°C. The reaction was stopped by sedimenting the beads with the magnet and  
35 removing the supernatant, followed by three washings with 50  $\mu$ l of water.

SEQUENCING BY SEQUENTIAL ADDITION OF SINGLE NUCLEOTIDES:

## SECOND COMPLETE CYCLE OF 9 STEPS

## scheme 1

steps 2 and 3

- 5 The beads (anchored template/primer complex 1) were resuspended in 4  $\mu$ l water. The following items were added: 2  $\mu$ l of 5 x sequenase buffer, 2  $\mu$ l of a nucleotide mixture containing 15  $\mu$ M fluorescein-12-dUTP, 1.0  $\mu$ M dTTP, 10  $\mu$ M ddGTP, 10  $\mu$ M ddATP, 10  $\mu$ M ddCTP, and 2  $\mu$ l of diluted
- 10 sequenase 2.0. The mixture was incubated for 2 min at 37°C and the reaction stopped by sedimenting the beads with the magnet and removing the supernatant followed by three further washings with 50  $\mu$ l of water. In this step, as directed by the complementary strand, fluorescein-labelled
- 15 U-nucleotides, T-nucleotides, and one dideoxy G-nucleotide were added to the 3'-end of the capped primer.

step 4

- The fluorescence was measured using a SIT camera (model C2
- 20 400-08, Hamamatsu Photonics SA) mounted on a fluorescence microscope.

steps 5 and 6

- The dideoxynucleotide and the labelled nucleotides were
- 25 removed by adding 10  $\mu$ l (20 units) of the above specified exonuclease-III solution and incubating the mixture for 2 min at 37°C. The reaction was stopped by sedimenting the beads with the magnet and removing the supernatant, followed by three washings with 50  $\mu$ l of water.

30

steps 7 and 8

- In order to cap the primer, the beads were resuspended in 4  $\mu$ l water. The following items were added: 2  $\mu$ l of 5 x sequenase buffer, 2  $\mu$ l of a nucleotide mixture containing 10
- 35  $\mu$ M d<sub>s</sub>TTP, 10  $\mu$ M ddGTP, 10  $\mu$ M ddATP, 10  $\mu$ M ddCTP, and 2  $\mu$ l of diluted sequenase 2.0. The mixture was incubated 2 min at 37°C and the reaction stopped by sedimenting the beads with the magnet and removing the supernatant followed by three

further washings with 50  $\mu$ l of water. In this step, two thiolated T-nucleotides and one dideoxy G-nucleotide were added to the sequencing primer.

5 steps 9 and 10

The dideoxy nucleotide was removed by adding 10  $\mu$ l (20 units) of the above specified exonuclease-III solution and incubating the mixture for 2 min at 37°C. The reaction was stopped by sedimenting the beads with the magnet and  
10 removing the supernatant, followed by three washings with 50  $\mu$ l of water.

EXAMPLE 8

PREPARATION OF THE DNA TEMPLATE/PRIMER COMPLEX 1

15

Template preparation, binding of the template to a solid support, and annealing the sequencing primer was performed as described in example 1.

20 Capping of the primer with thio nucleotides

To the 18  $\mu$ l annealing mixture add 10  $\mu$ l of 100  $\mu$ M d<sub>s</sub>GTP, ddATP, ddTTP, and ddCTP and 4  $\mu$ l (5 units) of diluted sequenase 2.0 (USB), and incubate the mixture for 2 min at room temperature. As directed by the complementary strand,  
25 this adds the following three nucleotides sequentially to the primer: d<sub>s</sub>G, d<sub>s</sub>G, ddC. The beads were sedimented using the magnet and the supernatant removed. The beads were then washed two times with 50  $\mu$ l water.

30 Removing the dideoxynucleotide from the capped primer

To the beads, 10  $\mu$ l (20 units) of an exonuclease solution in 50 mM Tris/HCl pH 7.5, 5mM MgCl<sub>2</sub>, 5 mM DTT were added and the mixture incubated 2 min at 37°C. The reaction was the reaction stopped by sedimenting the beads with the magnet  
35 and removing the supernatant, followed by three washings with 50  $\mu$ l of water. This step removed the dideoxy C-nucleotide from the 3'-end of the primer.



## FIRST SEQUENCING CYCLE (9 STEPS)

## scheme 1

steps 2 and 3

- 5 The beads (anchored template/primer complex 1) were resuspended in 4  $\mu$ l of water. The following items were added: 2  $\mu$ l 5 x sequenase buffer, 2  $\mu$ l of a nucleotide mixture containing 10  $\mu$ M fluorescein-15-dCTP (Boehringer Mannheim), 10  $\mu$ M ddGTP, 10  $\mu$ M ddATP, 10  $\mu$ M ddTTP, and 2  $\mu$ l  
10 of diluted sequenase 2.0. The mixture was incubated for 2 min at 37°C and stopped by sedimenting the beads with the magnet and removing the supernatant followed by three further washings with 50  $\mu$ l of water. In this step, as directed by the complementary strand, one fluorescein-  
15 labelled C-nucleotide and one dideoxy G-nucleotide were added to the 3'-end of the capped primer.

step 4

- The fluorescence was measured using a SIT camera (model C2  
20 400-08, Hamamatsu Photonics SA) mounted on a fluorescence microscope.

steps 5 and 6

- The dideoxynucleotide and the fluorescein-labelled  
25 nucleotides were removed by adding 10  $\mu$ l (20 units) of an exonuclease-III solution in 50 mM Tris/HCl pH 7.5, 5 mM MgCl<sub>2</sub>, 5 mM DTT and incubating the mixture for 2 min at 37°C. The reaction was stopped by sedimenting the beads with the magnet and removing the supernatant, followed by  
30 three washings with 50  $\mu$ l of water.

steps 7 and 8

- In order to cap the primer, the beads were resuspended in 4  $\mu$ l water. The following items were added: 2  $\mu$ l 5 x  
35 sequenase buffer, 2  $\mu$ l of a nucleotide mixture containing 10  $\mu$ M d<sub>s</sub>CTP, 10  $\mu$ M ddGTP, 10  $\mu$ M ddATP, 10  $\mu$ M ddTTP, and 2  $\mu$ l of diluted sequenase 2.0. The mixture was incubated 2 min at 37°C and the reaction stopped by sedimenting the beads with

the magnet and removing the supernatant followed by three further washings with 50  $\mu$ l of water. In this step, one thiolated C-nucleotide and one dideoxy G-nucleotide were added to the sequencing primer.

5

steps 9 and 10

The dideoxy nucleotide was removed by adding 10  $\mu$ l (20 units) of the above specified exonuclease-III solution and incubating the mixture for 2 min at 37°C. The reaction was  
10 stopped by sedimenting the beads with the magnet and removing the supernatant, followed by three washings with 50  $\mu$ l of water.

## SECOND SEQUENCING CYCLE (9 STEPS)

15 scheme 1steps 2 and 3

The beads (anchored template/primer complex 1) were resuspended in 4  $\mu$ l water. The following items were added:  
20 2  $\mu$ l 5 x sequenase buffer, 2  $\mu$ l of a nucleotide mixture containing 10  $\mu$ M fluorescein-15-dITP (Boehringer Mannheim), 10  $\mu$ M ddATP, 10  $\mu$ M ddTTP, 10  $\mu$ M ddCTP, and 2  $\mu$ l of diluted sequenase 2.0. The mixture was incubated 2 min at 37°C and the reaction stopped by sedimenting the beads with the  
25 magnet and removing the supernatant followed by three further washings with 50  $\mu$ l of water. In this step, as directed by the complementary strand, one fluorescein-labelled I-nucleotide and one dideoxy A-nucleotide were added to the 3'-end of the capped primer.

30

step 4

The fluorescence was measured using a SIT camera (model C2 400-08, Hamamatsu Photonics SA) mounted on a fluorescence microscope.

35

steps 5 and 6

The dideoxynucleotide and the labelled nucleotide were removed by adding 10  $\mu$ l (20 units) of an exonucleaseIII

solution in 50 mM Tris/HCl pH 7.5, 5 mM MgCl<sub>2</sub>, 5 mM DTT and incubating the mixture for 2 min at 37°C. The reaction was stopped by sedimenting the beads with the magnet and removing the supernatant, followed by three washings with 50 µl of water.

steps 7 and 8

In order to cap the primer, the beads were resuspended in 4 µl water. The following items were added: 2 µl 5 x sequenase buffer, 2 µl of a nucleotide mixture containing 10 µM d<sub>s</sub>GTP, 10 µM ddATP, 10 µM ddTTP, 10 µM ddCTP, and 2 µl of diluted sequenase 2.0. The mixture was incubated for 2 min at 37°C and the reaction stopped by sedimenting the beads with the magnet and removing the supernatant followed by three further washings with 50 µl of water. In this step, one thiolated G-nucleotide and one dideoxy A-nucleotide were added to the sequencing primer.

steps 9 and 10

The dideoxy nucleotide was removed by adding 10 µl (20 units) of the above specified exonuclease III solution and incubating the mixture for 2 min at 37°C. The reaction was stopped by sedimenting the beads with the magnet and removing the supernatant, followed by three washings with 50 µl of water.

THIRD SEQUENCING CYCLE (9 STEPS)

scheme 1

steps 2 and 3

The beads (anchored template/primer complex 1) were resuspended in 4 µl water. The following items were added: 2 µl 5 x sequenase buffer, 2 µl of a nucleotide mixture containing 10 µM fluorescein-15-dATP, 10 µM ddGTP, 10 µM ddTTP, 10 µM ddCTP, and 2 µl of diluted sequenase 2.0. The mixture was incubated for 2 min at 37°C and the reaction stopped by sedimenting the beads with a magnet and removing the supernatant followed by three further washings with 50

$\mu$ l of water. In this step, as directed by the complementary strand, two fluorescein-labelled A-nucleotides and one dideoxy T-nucleotide were added to the 3'-end of the capped primer.

5

step 4

The fluorescence was measured using a SIT camera (model C2 400-08, Hamamatsu Photonics SA) mounted on a fluorescence microscope.

10

steps 5 and 6

The dideoxynucleotide and the labelled nucleotides were removed by adding 10  $\mu$ l (20 units) of an exonuclease-III solution in 50 mM Tris/HCl pH 7.5, 5 mM  $MgCl_2$ , 5 mM DTT and incubating the mixture for 2 min at 37°C. The reaction was stopped by sedimenting the beads with the magnet and removing the supernatant, followed by three washings with 50  $\mu$ l of water.

20 steps 7 and 8

In order to cap the primer, the beads were resuspended in 4  $\mu$ l water. The following items were added: 2  $\mu$ l 5 x sequenase buffer, 2  $\mu$ l of a nucleotide mixture containing 10  $\mu$ M  $d_g$ ATP, 10  $\mu$ M ddGTP, 10  $\mu$ M ddTTP, 10  $\mu$ M ddCTP, and 2  $\mu$ l of diluted sequenase 2.0. The mixture was incubated 2 min at 37°C and the reaction stopped by sedimenting the beads with the magnet and removing the supernatant followed by three further washings with 50  $\mu$ l of water. In this step, two thiolated A-nucleotides and dideoxy T-nucleotide were added to the sequencing primer.

30

steps 9 and 10

The dideoxy nucleotide was removed by adding 10  $\mu$ l (20 units) of the above specified exonuclease III solution and incubating the mixture for 2 min at 37°C. The reaction was stopped by sedimenting the beads with the magnet and removing the supernatant, followed by three washings with 50  $\mu$ l of water.

35

## FOURTH SEQUENCING CYCLE (9 STEPS)

## scheme 1

5 steps 2 and 3

The beads (anchored template/primer complex 1) were resuspended in 4  $\mu$ l water. The following items were added: 2  $\mu$ l 5 x sequenase buffer, 2  $\mu$ l of a nucleotide mixture containing 10  $\mu$ M fluorescein-12-dUTP, 10  $\mu$ M ddGTP, 10  $\mu$ M ddATP, 10  $\mu$ M ddCTP, and 2  $\mu$ l of diluted sequenase 2.0. The mixture was incubated for 2 min at 37°C and the reaction stopped by sedimenting the beads with the magnet and removing the supernatant followed by three further washings with 50  $\mu$ l of water. In this step, as directed by the complementary strand, two fluorescein-labelled U-nucleotides and one dideoxy G-nucleotide were added to the 3'-end of the capped primer.

step 4

20 The fluorescence was measured using a SIT camera (model C2 400-08, Hamamatsu Photonics SA) mounted on a fluorescence microscope.

steps 5 and 6

25

The dideoxynucleotide and the labelled nucleotides were removed by adding 10  $\mu$ l (20 units) of an exonuclease-III solution in 50 mM Tris/HCl pH 7.5, 5 mM MgCl<sub>2</sub>, 5 mM DTT and incubating the mixture for 2 min at 37°C. The reaction was stopped by sedimenting the beads with the magnet and removing the supernatant, followed by three washings with 50  $\mu$ l of water. The removal of the label was checked by measuring the mixture with the hand counter.

35 steps 7 and 8

In order to cap the primer, the beads were resuspended in 4  $\mu$ l water. The following items were added: 2  $\mu$ l 5 x sequenase buffer, 2  $\mu$ l of a nucleotide mixture containing 10

$\mu\text{M}$   $d_s\text{TTP}$ ,  $10\ \mu\text{M}$   $dd\text{GTP}$ ,  $10\ \mu\text{M}$   $dd\text{ATP}$ ,  $10\ \mu\text{M}$   $dd\text{CTP}$ , and  $2\ \mu\text{l}$  of diluted sequenase 2.0. The mixture was incubated for 2 min at  $37^\circ\text{C}$  and the reaction stopped by sedimenting the beads with the magnet and removing the supernatant followed by  
5 three further washings with  $50\ \mu\text{l}$  of water. In this step, two thiolated T-nucleotides and one dideoxy G-nucleotide were added to the sequencing primer.

steps 8 and 9

10 The dideoxy nucleotide was removed by adding  $10\ \mu\text{l}$  (20 units) of the above specified exonuclease-III solution and incubating the mixture for 2 min at  $37^\circ\text{C}$ . The reaction was stopped by sedimenting the beads with the magnet and removing the supernatant, followed by three washings with  $50$   
15  $\mu\text{l}$  of water.

EXAMPLE 9

PREPARATION OF THE DNA TEMPLATE/PRIMER COMPLEX 1

Template preparation, binding of the template to solid  
20 support, and annealing of the sequencing primer was performed as described in example 1.

Capping of the primer with thionucleotides

To the  $18\ \mu\text{l}$  annealing mixture add  $10\ \mu\text{l}$  of  $100\ \mu\text{M}$   $d_s\text{GTP}$ ,  
25  $dd\text{ATP}$ ,  $dd\text{TTP}$ , and  $dd\text{CTP}$  and  $4\ \mu\text{l}$  (5 units) of diluted sequenase 2.0 (USB), and incubate the mixture for 2 min at room temperature. As directed by the complementary strand this adds the following three nucleotides sequentially to the primer:  $d_s\text{G}$ ,  $d_s\text{G}$ ,  $dd\text{C}$ . The beads were sedimented using  
30 the magnet and the supernatant removed. The beads were then washed two times with  $50\ \mu\text{l}$  water.

Removing the dideoxynucleotide from the capped primer

To the beads,  $10\ \mu\text{l}$  (20 units) of an exonuclease solution in  
35  $50\ \text{mM}$  Tris/HCl pH 7.5,  $5\ \text{mM}$   $\text{MgCl}_2$ ,  $5\ \text{mM}$  DTT were added and the mixture incubated 2 min at  $37^\circ\text{C}$ . The reaction was stopped by sedimenting the beads with the magnet and removing the supernatant, followed by three washings with

50  $\mu$ l of water. This step removed the dideoxy C-nucleotide from the 3'-end of the primer.

#### FIRST SEQUENCING CYCLE (9 STEPS)

##### 5 **scheme 1**

##### steps 2 and 3

The beads (anchored template/primer complex 1) were resuspended in 4  $\mu$ l water. The following items were added:  
10 2  $\mu$ l 5 x sequenase buffer, 2  $\mu$ l of a nucleotide mixture containing 15  $\mu$ M fluorescein-15-dCTP, 1.0  $\mu$ M dCTP, 10  $\mu$ M ddGTP, 10  $\mu$ M ddATP, 10  $\mu$ M ddTTP, and 2  $\mu$ l of diluted sequenase 2.0. The mixture was incubated for 2 min at 37°C and the reaction stopped by sedimenting the beads with the  
15 magnet and removing the supernatant followed by three further washings with 50  $\mu$ l of water.

##### step 4

The fluorescence was measured using a SIT camera (model C2  
20 400-08, Hamamatsu Photonics SA) mounted on a fluorescence microscope.

##### steps 5 and 6

The dideoxynucleotide and the fluorescein-labelled  
25 nucleotides were removed by adding 10  $\mu$ l (20 units) of an exonuclease-III solution in 50 mM Tris/HCl pH 7.5, 5 mM MgCl<sub>2</sub>, 5 mM DTT and incubating the mixture for 2 min at 37°C. The reaction was stopped by sedimenting the beads with the magnet and removing the supernatant, followed by  
30 three washings with 50  $\mu$ l of water.

##### steps 7 and 8

In order to cap the primer, the beads were resuspended in 4  $\mu$ l water. The following items were added: 2  $\mu$ l 5 x  
35 sequenase buffer, 2  $\mu$ l of a nucleotide mixture containing 10  $\mu$ M d<sub>s</sub>CTP, 10  $\mu$ M ddGTP, 10  $\mu$ M ddATP, 10  $\mu$ M ddTTP, and 2  $\mu$ l of diluted sequenase 2.0. The mixture was incubated 2 min at 37°C and the reaction stopped by sedimenting the beads with

the magnet and removing the supernatant followed by three further washings with 50  $\mu$ l of water. In this step, two thiolated C-nucleotides and one dideoxy G-nucleotide were added to the sequencing primer.

5

steps 9 and 10

The dideoxy nucleotide was removed by adding 10  $\mu$ l (20 units) of the above specified exonuclease III solution and incubating the mixture for 2 min at 37°C. The reaction was  
10 stopped by sedimenting the beads with the magnet and removing the supernatant, followed by three washings with 50  $\mu$ l of water.

## SECOND SEQUENCING CYCLE (9 STEPS)

15 scheme 1steps 2 and 3

The beads (anchored template/primer complex 1) were resuspended in 4  $\mu$ l water. The following items were added:  
2  $\mu$ l 5 x sequenase buffer, 2  $\mu$ l of a nucleotide mixture  
20 containing 500  $\mu$ M fluorescein-15-dITP, 1.0  $\mu$ M dGTP, 10  $\mu$ M ddATP, 10  $\mu$ M ddTTP, 10  $\mu$ M ddCTP, and 2  $\mu$ l of diluted sequenase 2.0. The mixture was incubated for 2 min at 37°C and the reaction stopped by sedimenting the beads with the magnet and removing the supernatant followed by three  
25 further washings with 50  $\mu$ l of water.

step 4

The fluorescence was measured using a SIT camera (model c2 400-08, Hamamatsu Photonics SA) mounted on a fluorescence microscope.

30

steps 5 and 6

The dideoxynucleotide and the labelled nucleotides were removed by adding 10  $\mu$ l (20 units) of an exonuclease-III solution in 50 mM Tris/HCl pH 7.5, 5 mM MgCl<sub>2</sub>, 5 mM DTT and  
35 incubating the mixture for 2 min at 37°C. The reaction was stopped by sedimenting the beads with the magnet and removing the supernatant, followed by three washings with 50  $\mu$ l of water.



steps 7 and 9

In order to cap the primer, the beads were resuspended in 4  $\mu$ l water. The following items were added: 2  $\mu$ l 5 x sequenase buffer, 2  $\mu$ l of a nucleotide mixture containing 10  $\mu$ M d<sub>g</sub>GTP, 10  $\mu$ M ddATP, 10  $\mu$ M ddTTP, 10  $\mu$ M ddCTP, and 2  $\mu$ l of diluted sequenase 2.0. The mixture was incubated 2 min at 37°C and the reaction stopped by sedimenting the beads with the magnet and removing the supernatant followed by three  
10 further washings with 50  $\mu$ l of water. In this step, one thiolated G-nucleotide and one dideoxy A-nucleotide were added to the sequencing primer.

step 9 and 10

15 The dideoxy nucleotide was removed by adding 10  $\mu$ l (20 units) of a specified exonuclease-III solution and incubating the mixture for 2 min at 37°C. The reaction was stopped by sedimenting the beads with the magnet and removing the supernatant, followed by three washings with 50  
20  $\mu$ l of water.

## THIRD SEQUENCING CYCLE (9 STEPS)

## scheme 1

25 steps 2 and 3

The beads (anchored template/primer complex 1) were resuspended in 4  $\mu$ l water. The following items were added: 2  $\mu$ l 5 x sequenase buffer, 2  $\mu$ l of a nucleotide mixture  
30 containing 500  $\mu$ M fluorescein-15-dATP, 1  $\mu$ M dATP, 10  $\mu$ M ddGTP, 10  $\mu$ M ddTTP, 10  $\mu$ M ddCTP, and 2  $\mu$ l of diluted sequenase 2.0. The mixture was incubated for 2 min at 37°C and the reaction stopped by sedimenting the beads with the magnet and removing the supernatant followed by three  
35 further washings with 50  $\mu$ l of water.

step 4

The fluorescence was measured using a SIT camera (model C2

400-08, Hamamatsu Photonics SA) mounted on a fluorescence microscope.

steps 5 and 6

- 5 The dideoxynucleotide and the labelled nucleotides were removed by adding 10  $\mu$ l (20 units) of an exonuclease-III solution in 50 mM Tris/HCl pH 7.5, 5mM  $MgCl_2$ , 5 mM DTT and incubating the mixture for 2 min at 37°C. The reaction was stopped by sedimenting the beads with the magnet and  
10 removing the supernatant, followed by three washings with 50  $\mu$ l of water.

steps 7 and 8

- In order to cap the primer, the beads were resuspended in 4  
15  $\mu$ l water. The following items were added: 2  $\mu$ l 5 x sequenase buffer, 2  $\mu$ l of a nucleotide mixture containing 10  $\mu$ M  $d_s$ ATP, 10  $\mu$ M ddGTP, 10  $\mu$ M ddTTP, 10  $\mu$ M ddCTP, and 2  $\mu$ l of diluted sequenase 2.0. The mixture was incubated 2 min at 37°C and the reaction stopped by sedimenting the beads  
20 with the magnet and removing the supernatant followed by three further washings with 50  $\mu$ l of water. In this step, two thiolated A-nucleotides and one dideoxy T-nucleotide were added to the sequencing primer.

25 steps 9 and 10

- The dideoxy nucleotide was removed by adding 10  $\mu$ l (20 units) of the above specified exonuclease-III solution and incubating the mixture for 2 min at 37°C. The reaction was stopped by sedimenting the beads with the magnet and  
30 removing the supernatant, followed by three washings with 50  $\mu$ l of water.

FOURTH SEQUENCING CYCLE (9 STEPS)

scheme 1

35 steps 2 and 3

- The beads (anchored template/primer complex 1) were resuspended in 4  $\mu$ l water. The following items were added: 2  $\mu$ l 5 x sequenase buffer, 2  $\mu$ l of a nucleotide mixture

containing 15  $\mu$ M fluorescein-12-dUTP, 1.0  $\mu$ M dTTP, 10  $\mu$ M ddGTP, 10  $\mu$ M ddATP, 10  $\mu$ M ddCTP, and 2  $\mu$ l of diluted sequenase 2.0. The mixture was incubated for 2 min at 37°C and the reaction stopped by sedimenting the beads with the magnet and removing the supernatant followed by three further washings with 50  $\mu$ l of water.

#### step 4

The fluorescence was measured using a SIT camera (model C2 400-08, Hamamatsu Photonics SA) mounted on a fluorescence microscope.

#### steps 5 and 6

The dideoxynucleotide and the labelled nucleotides were removed by adding 10  $\mu$ l (20 units) of an exonuclease-III solution in 50 mM Tris/HCl pH 7.5, 5 mM MgCl<sub>2</sub>, 5 mM DTT and incubating the mixture for 2 min at 37°C. The reaction was stopped by sedimenting the beads with the magnet and removing the supernatant, followed by three washings with 50  $\mu$ l of water. The removal of the label was checked by measuring the mixture with the hand counter.

#### steps 7 and 8

In order to cap the primer, the beads were resuspended in 4  $\mu$ l water. The following items were added: 2  $\mu$ l 5 x sequenase buffer, 2  $\mu$ l of a nucleotide mixture containing 10  $\mu$ M d<sub>s</sub>TTP, 10  $\mu$ M ddGTP, 10  $\mu$ M ddATP, 10  $\mu$ M ddCTP, and 2  $\mu$ l of diluted sequenase 2.0. The mixture was incubated 2 min at 37°C and the reaction stopped by sedimenting the beads with the magnet and removing the supernatant followed by three further washings with 50  $\mu$ l of water. In this step, two thiolated T-nucleotides and one dideoxy G-nucleotide were added to the sequencing primer.

#### steps 8 and 9

The dideoxy nucleotide was removed by adding 10  $\mu$ l (20 units) of the above specified exonucleaseIII solution and incubating the mixture for 2 min at 37°C. The reaction was

stopped by sedimenting the beads with the magnet and removing the supernatant, followed by three washings with 50  $\mu$ l of water.

- 5 It will be understood that the invention is described above by way of example only, and that a variety of modifications will be apparent to those skilled in the art which fall within the scope of the appended claims.

Claims

1. A method for determining the sequence of a nucleic acid comprising the steps of:
  - 5 a) forming a single-stranded template comprising the nucleic acid to be sequenced;
  - b) hybridising a primer to the template to form a  
10 template/primer complex;
  - c) extending the primer by the addition of a single labelled nucleotide;
  - 15 d) determining the type of the labelled nucleotide added onto the primer;
  - e) removing or neutralising the label; and
  - 20 f) repeating steps (c) to (e) sequentially and recording the order of incorporation of labelled nucleotides.
2. A method according to claim 1 wherein the  
25 template/primer complex is bound to a solid-phase support.
3. A method according to claim 1 or claim 2 wherein step (c) comprises the use of a mixture of both labelled and unlabelled nucleotides.
- 30 4. A method according to any preceding claim wherein the labelled nucleotide is added to the template/primer complex in the presence of chain elongation inhibitors.
5. A method according to claim 4 wherein the chain  
35 elongation inhibitors are chain terminators which are incorporated into the template/primer complex and step (e) further comprises removing the chain terminators.

6. A method according to claim 4 or claim 5 wherein the chain elongation inhibitor is a fluorescent dye group attached to the 3' moiety of the deoxyribose group of the labelled nucleotide, and step (e) comprises cleaving the  
5 fluorescent dye from the nucleotide to generate a 3' hydroxyl group.

7. A method according to claim 3 wherein the chain elongation inhibitors are not incorporated into the  
10 template/primer complex.

8. A method according to claim 7 wherein the chain elongation inhibitors are deoxynucleoside 5'-[ $\alpha$ ,  $\beta$ -methylene] triphosphates, deoxynucleoside diphosphates or  
15 deoxynucleoside monophosphates.

9. A method according to any preceding claim wherein the template/primer complex comprises a primer having a deoxynucleoside phosphorothioate base at its 3' end.  
20

10. A method according to claim 9 wherein step (e) comprises:

i) removing the labelled nucleotide with an exonuclease;  
25 and

ii) replacing the labelled nucleotide with a corresponding unlabelled phosphorothioate nucleoside derivative in the presence of chain elongation inhibitors.  
30

11. A method according to any preceding claim wherein steps (c) and (d) are repeated sequentially a multiplicity of times before the removal or neutralisation of the label.

35 12. A method according to any one of claims 1 to 8 wherein the label is a fluorescent label and step (e) comprises neutralising the label by bleaching with laser radiation or by chemical means, or by dissociating the label from the

labelled nucleotide.

13. A process for sequencing a DNA fragment comprising the steps of:

- 5 i) hybridizing a capped primer containing a phosphorothioate nucleoside derivative to a template to form a template/primer complex;
- 10 ii) adding a labelled deoxynucleoside triphosphate together with heterogenous chain terminators and a suitable polymerase to the template/primer complex;
- iii) removing excess reagents by washing;
- 15 iv) measuring the amount of incorporated label;
- v) treating the template/primer complex with an exonuclease to remove the label and the chain terminators;
- 20 vi) removing the exonuclease by washing;
- vii) adding a phosphorothioate deoxynucleoside triphosphate corresponding to the labelled deoxynucleoside triphosphate added in Step 2 together with heterogenous chain terminators;
- 25 viii) removing excess reagents by washing;
- 30 ix) treating the template/primer complex with an exonuclease to remove the chain terminators;
- x) removing the exonuclease by washing.
- 35 14. A process for sequencing a DNA fragment comprising the steps of:
  - i) hybridising a capped primer containing a

phosphorothioate nucleoside derivative to a template to form a template/primer complex;

ii) adding a labelled deoxynucleotide together with  
5 heterogeneous chain terminators and a suitable polymerase;

iii) removing excess reagents by washing;

iv) measuring the amount of incorporated label;  
10

v) removing the labelled nucleotide and the chain terminators with an exonuclease;

vi) removing the exonuclease by washing;  
15

vii) adding a phosphorothioate deoxynucleotide together with heterogeneous chain elongation inhibitors not incorporated into the chain; and

20 viii) removing excess reagents by washing;

15. A process for sequencing a DNA fragment comprising the steps of:

25 i) hybridising a capped primer containing a phosphorothioate deoxynucleotide to a template to form a template/primer complex;

ii) adding a labelled nucleotide triphosphate together  
30 with heterogeneous chain elongation inhibitors not incorporated into the chain;

iii) removing excess reagents by washing;

35 iv) measuring the amount of incorporated label;

v) repeating steps ii to iv until all four different labelled nucleotides in the presence of their corresponding



heterogeneous chain elongation inhibitors not incorporated into the chain have been added;

5 vi) removing all labelled nucleotides with exonuclease;

vii) removing the exonuclease by washing;

viii) adding the phosphorothioate deoxynucleotide corresponding to the first labelled deoxynucleotide added to  
10 the reaction in step ii, together with heterogeneous chain elongation inhibitors not incorporated into the chain and a suitable polymerase;

ix) removing excess reagents by washing;

15

x) repeating steps ix and x with the three remaining phosphorothioate deoxynucleoside derivatives.

16. A process for sequencing a DNA fragment comprising the  
20 steps of:

i) hybridising a capped primer to a template to form a template/primer complex;

25 ii) adding a fluorescent nucleoside triphosphate, together with three heterogeneous chain elongation inhibitors not incorporated into the chain and a suitable polymerase;

iii) removing excess reagents by washing;

30

iv) measuring the amount of incorporated label;

v) repeating steps ii to iv using all three different nucleoside triphosphates, each with a fluorescent label, in  
35 the presence of the respective heterogeneous chain elongation inhibitors not incorporated into the chain;

vi) destroying the fluorescent labels by bleaching with

a laser or by a suitable chemical reaction, or removing the fluorescent labels by a chemical cleavage step.

17. A process for sequencing a DNA fragment comprising  
5 steps of:

- i) hybridising a capped primer to a template;
- ii) adding a nucleoside triphosphate labelled by  
10 attachment of a fluorescent dye group via a linker arm to  
the 3' moiety of the deoxyribose sugar thereon;
- iii) removing the excess reagents by washing;
- 15 iv) measuring the amount of incorporated label;
- v) removing the fluorescent dye group by enzymatic  
cleavage; and
- 20 vi) removing excess reagents by washing.

18. A DNA sequencing kit comprising a plurality of the  
following:

- 25 i) a linker for attaching a DNA template to a solid-phase  
matrix, the linker comprising a primer having a  
deoxynucleoside phosphorothioate residue at its 3' end;
- ii) chain elongation inhibitors;
- 30 iii) fluorescently-labelled nucleoside triphosphates;
- iv) deoxynucleoside phosphorothioate triphosphates;
- 35 v) a 5'→3' DNA polymerase.
- vi) a 3'→5' exonuclease.

19. An automated sequencing machine capable of sequencing a nucleic acid essentially by executing the steps of a method according to any one of claims 1 to 15.
- 5 20. A process for sequencing a DNA fragment substantially as hereinbefore described, with reference to the examples.

## Quantitation of incorporated dUTP-12-fluorescein




figure 1

2/2

## Quantitation of incorporated dCTP-12-fluorescein




figure 2

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 93/00848

<b>I. CLASSIFICATION OF SUBJECT MATTER</b> (if several classification symbols apply, indicate all) <sup>6</sup> According to International Patent Classification (IPC) or to both National Classification and IPC Int.Cl. 5 C12Q1/68																							
<b>II. FIELDS SEARCHED</b> <div style="text-align: right; margin-right: 50px;">Minimum Documentation Searched<sup>7</sup></div> <table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 30%; border-bottom: 1px solid black; padding: 5px;">Classification System</td> <td style="border-bottom: 1px solid black; padding: 5px;">Classification Symbols</td> </tr> <tr> <td style="padding: 5px;">Int.Cl. 5</td> <td style="padding: 5px;">C12Q</td> </tr> </table> <div style="text-align: center; margin-top: 10px;"> <small>Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched<sup>8</sup></small> </div>			Classification System	Classification Symbols	Int.Cl. 5	C12Q																	
Classification System	Classification Symbols																						
Int.Cl. 5	C12Q																						
<b>III. DOCUMENTS CONSIDERED TO BE RELEVANT<sup>9</sup></b> <table style="width: 100%; border-collapse: collapse;"> <tr> <th style="width: 10%; border-bottom: 1px solid black; padding: 5px;">Category<sup>9</sup></th> <th style="width: 70%; border-bottom: 1px solid black; padding: 5px;">Citation of Document, <sup>11</sup> with indication, where appropriate, of the relevant passages <sup>12</sup></th> <th style="width: 20%; border-bottom: 1px solid black; padding: 5px;">Relevant to Claims No.<sup>13</sup></th> </tr> <tr> <td style="text-align: center; vertical-align: top; padding: 5px;">X</td> <td style="padding: 5px;">           WO,A,9 106 678 (SRI INTERNATIONAL)            16 May 1991            see the whole document  <div style="text-align: center;">---</div> </td> <td style="text-align: center; vertical-align: top; padding: 5px;">1-5</td> </tr> <tr> <td style="text-align: center; vertical-align: top; padding: 5px;">X</td> <td style="padding: 5px;">           WO,A,9 013 666 (AMERSHAM INTERNATIONAL)            15 November 1990            see abstract; claims  <div style="text-align: center;">---</div> </td> <td style="text-align: center; vertical-align: top; padding: 5px;">1,2</td> </tr> <tr> <td style="text-align: center; vertical-align: top; padding: 5px;">A</td> <td style="padding: 5px;">           EP,A,0 412 883 (BERTIN &amp; CIE)            13 February 1991  <div style="text-align: center;">---</div> </td> <td style="text-align: center; vertical-align: top; padding: 5px;">-</td> </tr> <tr> <td style="text-align: center; vertical-align: top; padding: 5px;">A</td> <td style="padding: 5px;">           EP,A,0 223 618 (NEW YORK MEDICAL COLLEGE)            27 May 1987  <div style="text-align: center;">---</div> </td> <td style="text-align: center; vertical-align: top; padding: 5px;">-</td> </tr> <tr> <td style="text-align: center; vertical-align: top; padding: 5px;">A</td> <td style="padding: 5px;">           WO,A,8 903 432 (U S DEPARTMENT OF ENERGY)            20 April 1989  <div style="text-align: center;">---</div> </td> <td style="text-align: center; vertical-align: top; padding: 5px;">-</td> </tr> <tr> <td colspan="2" style="text-align: right; padding: 5px;">-/--</td> <td></td> </tr> </table> <div style="margin-top: 10px;"> <div style="display: flex; justify-content: space-between;"> <div style="width: 45%;"> <p><sup>10</sup> Special categories of cited documents:</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="width: 45%;"> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</p> <p>"A" document member of the same patent family</p> </div> </div> </div>			Category <sup>9</sup>	Citation of Document, <sup>11</sup> with indication, where appropriate, of the relevant passages <sup>12</sup>	Relevant to Claims No. <sup>13</sup>	X	WO,A,9 106 678 (SRI INTERNATIONAL) 16 May 1991 see the whole document <div style="text-align: center;">---</div>	1-5	X	WO,A,9 013 666 (AMERSHAM INTERNATIONAL) 15 November 1990 see abstract; claims <div style="text-align: center;">---</div>	1,2	A	EP,A,0 412 883 (BERTIN & CIE) 13 February 1991 <div style="text-align: center;">---</div>	-	A	EP,A,0 223 618 (NEW YORK MEDICAL COLLEGE) 27 May 1987 <div style="text-align: center;">---</div>	-	A	WO,A,8 903 432 (U S DEPARTMENT OF ENERGY) 20 April 1989 <div style="text-align: center;">---</div>	-	-/--		
Category <sup>9</sup>	Citation of Document, <sup>11</sup> with indication, where appropriate, of the relevant passages <sup>12</sup>	Relevant to Claims No. <sup>13</sup>																					
X	WO,A,9 106 678 (SRI INTERNATIONAL) 16 May 1991 see the whole document <div style="text-align: center;">---</div>	1-5																					
X	WO,A,9 013 666 (AMERSHAM INTERNATIONAL) 15 November 1990 see abstract; claims <div style="text-align: center;">---</div>	1,2																					
A	EP,A,0 412 883 (BERTIN & CIE) 13 February 1991 <div style="text-align: center;">---</div>	-																					
A	EP,A,0 223 618 (NEW YORK MEDICAL COLLEGE) 27 May 1987 <div style="text-align: center;">---</div>	-																					
A	WO,A,8 903 432 (U S DEPARTMENT OF ENERGY) 20 April 1989 <div style="text-align: center;">---</div>	-																					
-/--																							
<b>IV. CERTIFICATION</b> <table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 50%; border-bottom: 1px solid black; padding: 5px;">           Date of the Actual Completion of the International Search  <div style="text-align: center;">01 SEPTEMBER 1993</div> </td> <td style="width: 50%; border-bottom: 1px solid black; padding: 5px;">           Date of Mailing of this International Search Report  <div style="text-align: center;">15. 09. 93</div> </td> </tr> <tr> <td style="border-bottom: 1px solid black; padding: 5px;">           International Searching Authority  <div style="text-align: center;">EUROPEAN PATENT OFFICE</div> </td> <td style="border-bottom: 1px solid black; padding: 5px;">           Signature of Authorized Officer  <div style="text-align: center;">MOLINA GALAN E.</div> </td> </tr> </table>			Date of the Actual Completion of the International Search <div style="text-align: center;">01 SEPTEMBER 1993</div>	Date of Mailing of this International Search Report <div style="text-align: center;">15. 09. 93</div>	International Searching Authority <div style="text-align: center;">EUROPEAN PATENT OFFICE</div>	Signature of Authorized Officer <div style="text-align: center;">MOLINA GALAN E.</div>																	
Date of the Actual Completion of the International Search <div style="text-align: center;">01 SEPTEMBER 1993</div>	Date of Mailing of this International Search Report <div style="text-align: center;">15. 09. 93</div>																						
International Searching Authority <div style="text-align: center;">EUROPEAN PATENT OFFICE</div>	Signature of Authorized Officer <div style="text-align: center;">MOLINA GALAN E.</div>																						

Form PCT/ISA/210 (second sheet) (January 1985)

## III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)

Category °	Citation of Document, with indication, where appropriate, of the relevant passages	Relevant to Claim No.
P,X	WO,A,9 305 183 (BAYLOR COLLEGE OF MEDICINE) 18 March 1993 see the whole document -----	1-5

Form PCT/ISA/210 (extra sheet) (January 1985)

**ANNEX TO THE INTERNATIONAL SEARCH REPORT  
ON INTERNATIONAL PATENT APPLICATION NO.**

GB 9300848  
SA 73679

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report.  
The members are as contained in the European Patent Office EDP file on  
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

01/09/93

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO-A-9106678	16-05-91	EP-A- 0450060	09-10-91
WO-A-9013666	15-11-90	EP-A- 0471732	26-02-92
		JP-T- 4505251	17-09-92
EP-A-0412883	13-02-91	FR-A- 2650840	15-02-91
		AU-A- 6180190	11-03-91
		CA-A- 2038932	12-02-91
		WO-A- 9102087	21-02-91
		JP-T- 4502862	28-05-92
EP-A-0223618	27-05-87	US-A- 4863849	05-09-89
		JP-A- 62085863	20-04-87
WO-A-8903432	20-04-89	US-A- 4962037	09-10-90
		EP-A- 0381693	16-08-90
		JP-T- 3502041	16-05-91
WO-A-9305183	18-03-93	AU-A- 2674092	05-04-93

EPO FORM P0478

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82